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The influence of body mass index on sensorimotor block and 
vasopressor requirement during spinal anaesthesia for 
elective caesarean section 
 
Introduction and aim of study 
 
Spinal anaesthesia (SA) using local anaesthetics and opiates is the preferred 
anaesthetic technique for elective and emergency caesarian section in both 
non-obese and morbidly obese parturients.   Hypotension following induction 
of SA is a common event1 leading to maternal dizziness, nausea and vomiting 
and impaired placental perfusion and fetal acidaemia.  In limited resource 
settings such as peripheral hospitals in South Africa, combined spinal – 
epidural anaesthesia, which allows for a reduction of the initial spinal dose 
and subsequent epidural top-up, is not a feasible option, particularly in the 
emergency situation.  Therefore single shot SA is favoured in most cases. 
 
A recent meta-analysis suggests that any reduction of the bupivacaine dose 
during single shot SA in the non-obese population to less than 10 mg, results 
in a significantly increased requirement for analgesic supplementation, and 
possibly conversion to general anaesthesia.2 Maternal weight may be a 
significant variable in predicting block height and consequent hypotension and 
the need for inotropes/vasopressors.  Many obstetric anaesthetists do adjust 
their dose regimen in morbidly obese patients, with a view to achieving 
adequate surgical anaesthesia while minimizing haemodynamic side effects.  
Current practice at our institution is to use the same standard dose of local 
anaesthetic and opiate for SA for caesarean section in both non-obese and 
morbidly obese parturients, since prolonged surgical time in obese patients is 
an important consideration.  In addition, a recent investigation suggests that 
the ED95 for spinal bupivacaine in obese patients is similar to that in non-
obese patients.3 Conversion to general anaesthesia for caesarean section in 
morbidly obese patients is associated with a significantly increased maternal 
and fetal risk.4 Therefore this study will compare an identical dose of spinal 
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bupivacaine of 10 mg, plus 10 µg fentanyl, in non-obese and morbidly obese 
patients.   
The primary outcome variable will be: 
• Vasopressor requirement (mean phenylephrine dose in the first 30
minutes after induction of SA)
The secondary outcome variables will be: 
• Maximum block height (touch and cold modalities)
• Time to regression to T6 of block height as assessed by cold
sensation, and to T10 as assessed by touch
• Adequacy of anaesthesia, as measured by requirement for analgesic
supplementation and conversion to general anaesthesia
• Measurements of motor block: hand grip strength and peak expiratory
flow
• Maternal side-effects such as nausea and vomiting
• Neonatal umbilical arterial blood gas values, and Apgar scores
Hypothesis 
The hypothesis of this study is that there will be no difference between the 
groups with regard to vasopressor requirement. 
Patients and Methods 
Approval for the study will be obtained from the Health Sciences Faculty 
Human Research Ethics Committee of the University of Cape Town.  The 
study will be performed at the Groote Schuur Hospital Maternity Centre and at 
Mowbray Maternity Hospital.  Written informed consent will be obtained at the 
time of recruitment.  Two groups of 25 patients per group requiring elective 
caesarean section will be recruited.  One group will comprise women with 
normal body mass index (BMI), defined as 32 kg/m2, and the other group will 
comprise morbidly obese parturients with a BMI of ≥ 40 kg/m2.  
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Inclusion criteria will be: 
• ASA Class 1 and 2
• Gestational age 37 completed weeks
• Singleton pregnancy
• Elective caesarean section
Exclusion criteria will be: 
• Patient refusal
• Pre-existing hypertension, or preeclampsia
• Any contraindication to SA
• Multiple pregnancy
• Urgent or emergency caesarean section
• Gestational age < 37 completed weeks
• Patients in whom obstetric haemorrhage is likely, i.e.
o More than 2 previous caesarean sections
o Placenta praevia
• Labour
• Inability to understand the procedure for testing for dermatome height
of the neuraxial block
• Failed SA
Prior to the surgical procedure, each patient will be visited in the ward by the 
anaesthesiologist, who will familiarise her with the testing procedure to 
determine the dermatome level of the neuraxial block using light touch and 
cold sensation. 
On arrival in theatre, IV access will be secured with at least an 18G cannula, 
30 mL of 0.3 M Sodium Citrate will be administered per os and intravenous 
Cefazolin, 1 or 2 g depending on maternal weight below or above 80 kg. 
Standard monitoring will be applied as per South African Society of 
Anaesthesiologists (SASA) guidelines, consisting of 3 lead ECG, pulse 
oximeter and non-invasive blood pressure monitoring.  An appropriate sized 
blood pressure (BP) cuff for noninvasive BP measurements will be applied.  
According to the American Heart Association, the width of the compression 
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bladder should be equal to 40% of the circumference or 1.2 times the 
diameter of the extremity.5   The diameter or circumference of the extremity is 
measured at midpoint of the limb.  For the arm, midpoint is measured at half 
the distance between the shoulder and the elbow joints.  If the patient’s limb 
measurement is on the borderline of two different cuff sizes the likelihood of 
an erroneous measurement is decreased if the larger of the two cuff sizes is 
used.  Cuffs that are wrapped too loosely result in falsely elevated values.  
Cuffs will be applied snugly, allowing only enough room for one finger to be 
slipped between the cuff and the skin surface.  Baseline mean arterial blood 
pressure will be recorded with the patient lying in the left lateral position.  It 
will be the average of three readings, which are within 10% of each other, 
measured during the five minutes prior to sitting up for SA.  SA will be 
administered using aseptic technique with the patient in the sitting position.  
After skin infiltration with lignocaine, a 25G Whitacre spinal needle or a 103 
mm Braun Pencan needle will be inserted at the L3/4 intervertebral space.  
After the subarachnoid space has been identified, a rapid infusion of Ringers 
Lactate 20 mL/kg will be administered.  Subarachnoid injection will consist of 
2 mL of hyperbaric 0.5% bupivacaine and 10 µg of fentanyl.  The patient will 
then be placed supine, and a wedge placed under the right flank to achieve a 
150 left lateral tilt.  Bilateral sensory block height will be monitored 5 minutes 
after induction of SA, using both the light touch and cold sensation modalities 
in response to ethyl chloride spray.6 Surgery will commence on achieving a 
bilateral sensory block of cold sensation to the T4 dermatome level.  Block 
height will be assessed again at 25 minutes, by which time maximum block 
height would have been reached.  This will be repeated on completion of 
surgery.  Strength of hand-grip, as measured by dynamometry, will be used to 
ensure that high motor block has not occurred (C8-T1 or higher).  A peak flow 
meter will be used to assess the effect of SA on respiratory function.  Hand- 
grip strength and peak flow readings will be taken in the induction room in the 
supine/wedged position (baseline), and 30 minutes after induction of SA.  
Haemodynamic data including systolic, diastolic and mean arterial pressure 
and heart rate (HR) will be recorded every minute for the duration of surgery.  
Hypotension, defined as a 20% decrease from baseline mean arterial 
pressure (MAP), will be treated with intravenous phenylephrine 50 µg.  A 30% 
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decrease in MAP, or failure to restore blood pressure to within 20% of 
baseline value within the first minute after the administration of 50 µg, will be 
treated with 100 µg of phenylephrine.  If HR decreases to less than 55 beats 
per minute in association with hypotension (MAP decrease by 30% from 
baseline), ephedrine 10 mg will be administered, followed by atropine 0.25-0.5 
mg if bradycardia persists.  Ephedrine may also be administered if there is a 
poor response to two consecutive doses of phenylephrine.  Associated 
nausea and vomiting will be treated with IV metoclopramide 10mg.  If a 
patient should report discomfort during surgery, 50% nitrous oxide/oxygen will 
be administered via facemask, and further analgesia can be provided if 
necessary with up to 4 boluses of 250 µg of alfentanil.  Continued discomfort 
will necessitate conversion to a general anaesthetic.  After delivery, 3 units of 
oxytocin will be administered IV during one minute. 
Time intervals to be noted will be: 
a. Time from arrival in theatre until induction of
anaesthesia
b. Time to T4 sensory block level
c. Induction to skin incision time
d. Induction to uterine incision time
e. Uterine incision to delivery time
f. Skin incision to closure
Adequacy of SA will be scaled as follows: 
Grade 1:  No supplementation required. 
Grade 2:  Analgesic supplementation required as per protocol. 
Grade 3:  Conversion to general anaesthesia required. 
Bloodloss will be estimated by measurement in a graded suction bottle, 
and by observation of swabs.  In patients in whom blood loss is 
estimated at 1 litre, vasopressor requirements from that time onwards 
will not be used to estimate total vasopressor requirement in that patient.  
Time to regression to T6 of block height as assessed by cold sensation, 
and to T10 as assessed by touch, will be measured in recovery room. 
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Calculation of sample size 
With regard to the primary outcome variable, namely total phenylephrine 
dose, a clinically relevant between-group difference in mean vasopressor 
requirement is 200 µg.  Assuming a standard deviation of 200 µg in each 
group, using a two-tailed t-test for independent samples, group sizes of 21 per 
group will be required to detect such a difference with 80% power and 
assuming an alpha error of 0.051"/>†.    
In addition, according to clinical experience, subarachnoid injection of 
hyperbaric bupivacaine 10 mg and fentanyl 10 µg as described above, usually 
produces sensory block up to the T3 dermatome (range T1 to T5).  A difference 
of one dermatome in block height in the obese group would be regarded as 
clinically important (for example up to T2 dermatome (range C8 to T4)).  Similar 
power and alpha as for vasopressor requirement would be obtained using 16 
patients per group.‡  In order to reduce allow for greater than anticipated 
variability in vasopressor response, and for the possibility that the occasional 
cervical block may be missed if a small number of patients are recruited, it is 
therefore intended to study a total of 50 patients. 
1"/>† Calculated using the method described by Columb and Stevens (2008).25 
‡ Medcalc Statistical Software, version 12.3.0.0 (MedCalc Software, Mariakerke, Belgium). 
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Data analysis 
Numerical, between-group data will be compared using two-tailed t-tests for 
independent samples.  Within-group data will be analysed using analysis of 
variance for repeated measures.  If data do not meet the requirements for 
normal distribution and equivalence of variance, then nonparametic, 
distribution-free tests (e.g. Mann-Whitney, Freedman) will be employed.  
Nonparametric tests will also be employed for analysis of ordinal, categorical 
data.  Proportional data will be analysed using Chi-squared or Fisher’s exact 
tests.  A p-value of 0.05 or less will be regarded as indicating statistical 
significance. 
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Part B: Descriptive Literature review 
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Dose regimen for spinal anaesthesia for caesarean section in morbidly 
obese patients 
1. Objectives
This literature review aims to assess current literature on the influence of body 
mass index on bupivacaine dosing for single shot spinal anaesthesia (SA) for 
caesarean section (CS).  The correct dose regimen for SA in morbidly obese 
parturients remains controversial amongst obstetric anaesthetists, since some 
practitioners perceive block height and concomitant hypotension as 
unpredictable in these patients. 
2. Literature Search Strategy
The full text of relevant publications was obtained online, from the University
of Cape Town Health Science Library search facility, which accesses 17
medical digital archive databases worldwide.  Literature published in the
English language before and including the year 2014 was included.
3. Quality criteria
The following keywords in various combinations were used for the search:
spinal anaesthesia, pregnancy, body mass index, obesity, caesarean section,
subarachnoid spread, block height assessment, hypotension, bupivacaine,
and fetal outcome.  The reference list was also used to identify further
appropriate papers.
4. Review and critical appraisal of the literature
4.1 Introduction 
Obesity is defined simply as a condition of abnormal or excessive fat 
accumulation in adipose tissue to the extent that health may be impaired.  The 
WHO characterises obesity as a pandemic with the prevalence higher in 
women than men.7 Consequently the obstetric anaesthetist is increasingly 
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confronted with the problem of anaesthetising obese parturients. Spinal 
anaesthesia (SA), using bupivacaine and opiates is the preferred technique to 
provide anaesthesia for elective and emergency CS.  Maternal hypotension 
due to sympathetic blockade is a common and feared consequence of SA,1 
which often leads to maternal dizziness, nausea/ vomiting, and placental 
hypoperfusion, thus compromising maternal and fetal outcome.   Combined 
spinal epidural (CSE) anaesthesia, which allows for reduction of the initial 
spinal dose and subsequent epidural top-up, is an attractive option commonly 
practiced in highly resourced units.  However, CSE is not feasible in resource-
limited peripheral hospitals in South Africa and for emergency caesarean 
section.  The epidural catheter also remains “unproven” during the duration of 
SA, which poses a risk for failure of anaesthesia when SA regresses. 
Continuous spinal anaesthesia (CSA) has also been postulated to be an 
option for CS in the morbidly obese, but is technically difficult and may be 
associated with post-dural puncture headache and infection.8,9 For this reason 
single shot SA is the preferred technique in most cases.  Maternal weight may 
be a significant variable in predicting block height and consequent 
hypotension and the need for vasopressors/inotropes.  Many obstetric 
anaesthetists adjust their dose regimen in morbidly obese patients, with a 
view to achieving adequate surgical anaesthesia while minimising 
haemodynamic side effects.  Conversion to general anaesthesia for 
caesarean section in morbidly obese patients is associated with a significantly 
increased risk of difficult intubation,10 which may result in poor maternal and 
neonatal outcome.  Current practice at our institution is to use an identical 
dose of local anaesthetic and opiate for CS in both non-obese and morbidly 
obese parturients, since prolonged surgical time in obese patients is an 
important consideration, and a reduction in dose could compromise surgical 
anaesthesia.   
4.2 Anatomical considerations within the vertebral canal during 
pregnancy 
The effective capacity of the extradural and subarachnoid spaces is reduced 
in supine parturients as a result of the engorged extradural venous plexus.11    
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This reduced capacity results in a compensatory reduction in cerebrospinal 
fluid (CSF) volume.  Hogan et al.12 in a magnetic resonance imaging (MRI) 
study also suggested further reduction of the CSF volume in patients with a 
high body mass index (BMI).  Various mechanisms that exert external 
pressure on the dural sac have been proposed for the lower CSF volume: 
increased intra-abdominal pressure from abdominal fat; epidural venous 
plexus engorgement secondary to inferior vena cava compression and 
diversion of venous return; and the inward movement of soft tissue in the 
intervertebral foramen displacing CSF.  These changes in addition to possible 
enhanced neural susceptibility to local anaesthetics in pregnant women result 
in a 25% reduction in dose requirement for spinal and epidural anaesthesia 
compared to the non-pregnant state. 
4.3 Relationship between block height and body mass index 
An early investigation showed a tendency towards higher cephalad spread of 
local anaesthetic, more rapid onset and more rapid recovery from anaesthesia 
in obese non- pregnant patients receiving isobaric intrathecal bupivacaine, 
compared with patients with a normal BMI.13 However, these observations are 
of limited clinical relevance in predicting subarachnoid spread of hyperbaric 
local anaesthesia in morbidly obese parturients.  The studies investigating the 
relationship between patient variables (weight and height) and block height 
are limited and show conflicting results.7-11 Norris et al.14,15 showed no 
correlation between the height of sensory block and patient BMI.  In these 
studies, morbidly obese patients were not included, and a fixed dose of up to 
15 mg hyperbaric bupivacaine with morphine 150 μg was used.  Hodgkinson 
et al.16 showed a positive correlation between obesity and the cephalad 
spread of epidural bupivacaine in parturients undergoing either elective or 
emergency caesarean section.  However, this study did not include morbidly 
obese patients and despite sensory blocks up to C5 dermatome level in some 
obese patients, no respiratory embarrassment was demonstrated.  Vertebral 
column length was also suggested as an important variable with regard to 
local anaesthetic spread within the subarachnoid space, but no correlation 
has been shown.17 In their randomized control trial Harten et al. suggest that 
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adjusting the SA dose regimen for cesarean section according to the patient’s 
weight and height results in less hypotension and fewer blocks above T1 
dermatome level.18 Patients were randomised to receive a fixed dose of 12 
mg hyperbaric bupivacaine and 0,4 mg diamorphine, or an adjusted dose 
using a chart taking height and weight into account.  The adjusted dose group 
received a median [IQR] dose of hyperbaric bupivacaine of 9.5 [9-10] mg.  In 
the fixed dose group six patients experienced loss of sensation to pinprick 
above T1 dermatome, and three patients to C8 but no patients required 
ventilator support.  On the other hand some patients in the adjusted dose 
group required supplementation of analgesia suggesting that adjusting the 
dose according to patient’s weight might result in inadequate anaesthesia for 
caesarean section.  The use of dose charts is not common practice at our 
institution and clinical experience is that 12 mg is too high a subarachnoid 
dose for our patient population while 9 mg increases the possibility of 
maternal discomfort requiring analgesia supplementation. 
4.4 Evidence for spinal bupivacaine dose/response 
The proposed advantages of minimising the intrathecal dose of hyperbaric 
bupivacaine include: reduced incidence of maternal hypotension, reduced 
vasopressor requirement, reduced incidence of nausea/vomiting and shorter 
discharge times from post anaesthesia care unit.19,20 However, a recent 
review cautions against the use of low dose SA for CS, in view of the risk of 
inadequate anaesthesia.21 A recent meta-analysis suggests that any 
reduction of the bupivacaine dose during single shot SA in the non-obese 
population to less than 8 mg, results in significantly increased requirement for 
analgesic supplementation and possibly conversion to general anaesthesia.2 
The authors reviewed low dose (LD) bupivacaine group (≤ 8 mg) and 
conventional dose (CD) bupivacaine group (> 8 mg) for elective or semi-
urgent caesarean section.  With regards to their primary outcome namely 
anaesthetic efficacy as measured by intraoperative anaesthetic/analgesic 
supplementation, the risk was three times higher in the LD bupivacaine group 
(RR=3.76, 95% CI= 2.38- 5.98, P< 0.00001) than the CD bupivacaine group.  
The dermatomal block height ranged between T2 – T6, however, there was 
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heterogeneity in the assessment methods used.  Despite the proposed lower 
risk of maternal side effects in LD than CD (22% reduction in hypotension and 
29% reduction in nausea and vomiting) 15, low dose spinal anaesthesia may 
not be the optimal technique for all patients especially if surgical time is likely 
to be prolonged and conversion to general anaesthesia poses a much higher 
maternal and neonatal risk.  The potency of local anaesthetics is expressed in 
terms of the minimum effective concentration or dose (EC50 or ED50 and 
ED95).  In non-obese parturients the ED50 and ED95 for hyperbaric bupivacaine 
with opiate has been shown to be 7.6 mg and 11.2 mg respectively.22 The 
authors also caution against dose reduction for hyperbaric bupivacaine doses 
for SA.  Doses less than the ED95 and ED50 showed a 5% and 50% failure 
rate, respectively.  In a further recent publication Lee et al23 suggested the 
ED95 for intrathecal hyperbaric bupivacaine in obese patients (BMI more than 
30 kg/m2) to be 12.92 mg (95% CI: 11.49 – 34.77) which is similar to that in 
non-obese patients.  This study is limited by use of historical control and the 
design was different to that used in the original study for the control group.  A 
recent investigation, which is also limited by the use of historical controls, 
suggests that the ED95 for spinal bupivacaine with opiates in morbidly obese 
patients is 15 mg (CI 10.0 – 20.0), which is similar to that in non-obese 
patients.3 Morbidly obese patients in the study (BMI ≥ 40 kg/m2) undergoing 
elective CS under combined spinal epidural were randomly assigned to 
receive up to 11 mg intrathecal hyperbaric bupivacaine with 200 μg morphine 
and 10 μg fentanyl.  The primary outcome was success or failure of the 
intrathecal block.  A block was regarded as successful if a T6 sensory level to 
pinprick was obtained within ten minutes of induction of SA with no epidural 
supplementation required during the operation.  The adequacy of analgesia 
was assessed using a visual analogue scale and epidural supplementation 
was provided with score of 20mm and above as well as on patient request.  
Even with this modest dose of hyperbaric bupivacaine for SA, greater 
incidence or severity of hypotension or significant differences in the incidence 
of nausea and vomiting was not demonstrated.  However, this study was not 
adequately powered to detect differences in the incidence or severity of 
hypotension or incidence of nausea and vomiting with doses above 10 mg.  
The authors conclude that morbidly obese and non-obese patients show a 
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similar response to modest doses of intrathecal hyperbaric bupivacaine.  
However, the dose response in the obese population is variable, but doses 
less than 10 mg (i.e. doses < 95% CI value) are not recommended.  These 
findings do however support our hypothesis that the dose requirement for 
spinal bupivacaine for caesarean delivery is similar in morbidly obese and 
non-obese patients.  Finally, a retrospective analysis suggests that high 
cephalad spread of bupivacaine is unlikely unless the BMI is higher than 50 
kg/m2.24  
4.4 Proposed study 
To our knowledge there is no published prospective comparison of identical 
dose spinal bupivacaine for CS in morbidly obese versus normal BMI 
parturients.  In addition, more than 1000 morbidly obese parturients have 
received SA for CS employing 10 mg hyperbaric bupivacaine with 10 μg 
fentanyl during the past 3 years at our institution.  It was therefore decided to 
study 2 groups of patients, one in the low BMI range, and the other in the 
morbidly obese category, and assess block height, vasopressor requirement 
and surgical anaesthesia.    
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It has been suggested that the dose requirement for spinal anesthesia (SA) is 
lower in obese patients for cesarean delivery.  In this prospective, 
observational, non-inferiority study we tested the hypothesis that obesity 
would not have a clinically important effect on vasopressor requirements or 
block height. 
Methods 
Two groups of 25 parturients, Group O (BMI >40 kg/m2) and Group N (BMI 
<32 kg/m2) requiring elective cesarean delivery were recruited.  All patients 
received 10 mg intrathecal hyperbaric bupivacaine co-administered with 10 μg 
fentanyl.  Dermatomal levels were assessed at 5 and 25 minutes after SA, 
and at completion of surgery, using light touch and cold sensation in response 
to ethyl chloride.  The primary outcomes were phenylephrine requirement in 
the first thirty minutes following spinal anesthesia, and maximum block height, 
measured by the sensation of touch and cold.  Secondary outcomes were 




There were no significant between-group differences in median block height 
as assessed by touch at 5 or 25 minutes, or by temperature at 5 minutes.  At 
25 minutes, there was a two-dermatome difference in median block height for 
loss of temperature sensation between Group O and Group N (T2 vs. T4, 
95% confidence interval (CI) of the difference in medians 0-2 dermatomes).  
No blocks extended to cervical dermatomes.  The median (range) 
phenylephrine dose for the first 30 minutes was 150 µg (0-900 µg), and 100 
µg (0-1250 µg) in Group N and O respectively.  The 95% CI for the difference 
between the two median doses was -150 µg to 100 µg.  There were no 
differences in median percentage reductions in peak flow rate or median hand 
grip strength after SA.  Mean surgical time was longer in Group O than in 
Group N (49.1 vs 39.4 minutes, 95% CI difference 1.7 to 17.7 minutes).  The 
mean time for recovery of touch sensation to T10 was longer in Group O (152 
vs 132 minutes, 95% CI difference 3.8 to 36.2 minutes).  No analgesic 
supplementation was required. 
Conclusion 
Only a minor increase block height as assessed by temperature occurred in 
Group O at 25 minutes.  Vasopressor requirements during the first 30 min of 
SA were equivalent.  Time for regression of SA block level was longer in the 
Group O, which may be beneficial considering the longer surgical time.  A 
dose of spinal bupivacaine 10 mg for single-shot SA should not be reduced in 




Regional anaesthesia using local anesthetics and opiates is the preferred 
anesthetic technique for elective and emergency caesarean section in both 
non-obese and morbidly obese parturients.  Hypotension following induction 
of spinal anesthesia (SA) is a common event,1 leading to maternal dizziness, 
nausea and vomiting, impaired placental perfusion and fetal acidaemia. 
Morbidly obese patients pose particular challenges to the anesthesiologist.  In 
limited resource settings such as peripheral hospitals in South Africa, 
combined spinal – epidural anesthesia, which allows for a reduction of the 
initial spinal dose and subsequent epidural top-up, is not a feasible option, 
particularly in the emergency situation.  Therefore single shot SA for morbidly 
obese parturients is favoured in most cases. 
A recent meta-analysis suggests that any reduction of the bupivacaine dose 
during single shot SA in the non-obese population to less than 8 mg, results in 
a significantly increased requirement for analgesic supplementation.2  
Maternal weight may be a significant variable in predicting block height and 
consequent hypotension and the need for inotropes/vasopressors.  Many 
obstetric anesthetists do adjust their dose regimen in morbidly obese patients, 
with a view to achieving adequate surgical anesthesia while minimising 
hemodynamic side effects.  Current practice at our institution is to use the 
same standard dose of local anesthetic and opiate for SA for caesarean 
section in both non-obese and morbidly obese parturients, since prolonged 
surgical time in obese patients is an important consideration.  In addition, two 
recent investigations suggest that the ED95 for spinal bupivacaine in obese 
patients is similar to that in non-obese patients.3;4  Conversion to general 
anesthesia for caesarean section in morbidly obese patients is associated 
with a significantly increased maternal and fetal risk.  Therefore this study 
compared an identical dose of spinal bupivacaine of 10 mg, plus 10 µg 
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fentanyl, our usual practice, in non-obese and morbidly obese patients.  The 
primary outcome variables were mean vasopressor requirement 
(phenylephrine) in the first 30 minutes after induction of SA, and maximum 
block height as measured by the sensation of touch and cold.  Secondary 
outcomes were surrogate measurements of the extent of motor block (hand 
grip strength and peak flow rate), pertinent time intervals relating to the 
procedure, including time to regression of block, adequacy of anesthesia, 
maternal side effects, and early neonatal outcome.  
Methods 
This was a stratified cohort study.  Approval for the study was obtained from 
the Health Sciences Faculty Human Research Ethics Committee of the 
University of Cape Town (HREC/REF:031/2013).  The study was performed 
at the Groote Schuur Hospital Maternity Centre and at Mowbray Maternity 
Hospital, Cape Town, South Africa.  Written informed consent was obtained at 
the time of recruitment, at least 12 hours before SA for elective CS.  Two 
groups of 25 patients were recruited with widely differing body mass indices, 
in order to examine the influence of body mass index (BMI) on the responses 
to a specific dose of spinal bupivacaine.  One group comprised women with 
BMI < 32 kg.m-2 (Group N), and the other group had a BMI of > 40 kg.m-2  
(Group O).  For consistency, parturients were weighed at the time of 
recruitment, since the investigating team did not have access to the 
participants in early pregnancy.   
Inclusion criteria were: ASA Class 1 and 2, gestational age > 37 completed 
weeks, singleton pregnancy, and elective caesarean section. 
Exclusion criteria were: Patient refusal, pre-existing hypertension, or 
preeclampsia, any contraindication to SA, multiple pregnancy, urgent or 
emergency caesarean section, patients in whom obstetric haemorrhage was  
likely, i.e. more than 2 previous caesarean sections, placenta praevia, active 
labour, inability to understand the procedure for testing for dermatome height 
of the neuraxial block, or failed SA. 
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Prior to the surgical procedure, each patient was visited in the ward by the 
anesthesiologist, who familiarised her with the testing procedures to 
determine the dermatome level of the neuraxial block using the modalities 
touch and cold sensation. 
On arrival in theatre, IV access was secured with an 18G cannula; 30 mL of 
0.3 M Sodium Citrate was administered per os, and intravenous Cefazolin 1 
or 2 g, depending on maternal weight below or above 80 kg.  Standard 
monitoring was applied, consisting of 3 lead ECG, pulse oximeter and non-
invasive blood pressure monitoring.  An appropriate sized blood pressure 
(BP) cuff for noninvasive BP measurements was applied.  According to the 
American Heart Association, the width of the compression bladder should be 
equal to 40% of the circumference or 1.2 times the diameter of the extremity.5
The diameter or circumference of the extremity is measured at midpoint of the 
limb.  For the arm, midpoint is measured at half the distance between the 
shoulder and the elbow joints.  If the patient’s limb measurement is on the 
borderline of two different cuff sizes the likelihood of an erroneous 
measurement is decreased if the larger of the two cuff sizes is used.  Cuffs 
that are wrapped too loosely result in falsely elevated values.  Cuffs were 
applied snugly, allowing only enough room for one finger to be slipped 
between the cuff and the skin surface.  Baseline mean arterial blood pressure 
was recorded with the patient lying in the left lateral position.  It was the 
average of three readings, within 10% of each other, measured during the five 
minutes prior to sitting up for SA.  SA was administered using aseptic 
technique with the patient in the sitting position.  After skin infiltration with 
lignocaine, a 90- or 103 mm 25G pencil-point spinal needle was inserted at 
the L3/4 intervertebral space.  After the subarachnoid space had been 
identified, a rapid infusion of Ringers Lactate 20 mL/kg was commenced.  
Subarachnoid injection consisted of 2 mL (10 mg) of hyperbaric 0.5% 
bupivacaine and 10 µg of fentanyl.  The patient was then placed supine, and 
a wedge placed under the right flank to achieve a 150 left lateral tilt.  Bilateral 
sensory block height, in the mid-clavicular line, was monitored 5 minutes after 
induction of SA, using both the light touch and cold sensation modalities in 
response to ethyl chloride.  For the assessment of block height for touch, 
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single drops of ethyl chloride were used, starting at blocked abdominal 
segments and progressively moving cephalad to unblocked segments.  The 
patient was asked the question, “Can you tell me when you feel something 
touching your skin”.  For block height for temperature sensation, single drops 
of ethyl chloride were again used, moving caudad from unblocked cervical 
segments to blocked segments.  In this case the patient was first asked, “How 
does this feel?”, when a drop of ethyl chloride made contact with her neck. 
They were then asked the open-ended question, "Is there any difference 
here?", while working cephalad from the T8 dermatome until the patient 
volunteered that they felt the sensation of cold.  Surgery was allowed to 
commence on achieving a bilateral sensory block of cold sensation to the T4 
dermatome level.  Block height was assessed again at 25 minutes, by which 
time maximum block height should have been reached.  This was repeated on 
completion of surgery.  Strength of hand-grip, as measured by dynamometry 
(JAMAR®, Lafayette Instruments Co., Indiana, USA), was used to assess 
whether high motor block had occurred (T1-C8 or higher).  A peak flow meter 
(Mini-Wright, Clement Clark International Ltd, UK) was used to assess the 
effect of SA on respiratory function.  Hand-grip strength and peak flow 
readings were taken in the induction room in the supine/wedged position 
(baseline), and 30 minutes after induction of SA.   
Haemodynamic data including systolic, diastolic and mean arterial pressure 
and heart rate (HR) were recorded every minute for the duration of surgery.  
Hypotension, defined as a 20% decrease from baseline mean arterial 
pressure (MAP), was treated with intravenous phenylephrine 50 µg.  A 30% 
decrease in MAP, or failure to restore blood pressure to within 20% of 
baseline value within the first minute after the administration of 50 µg, was 
treated with 100 µg of phenylephrine.  If HR were to decrease to less than 55 
beats per minute in association with hypotension (MAP decrease by 30% from 
baseline), ephedrine 10 mg would be administered, followed by atropine 0.25-
0.5 mg if bradycardia persisted.  Ephedrine was also administered if there 
was poor response to two consecutive doses of phenylephrine.  Associated 
nausea and vomiting was treated with IV metoclopramide 10 mg.  If a patient 
reported discomfort during surgery, 50% nitrous oxide/oxygen was 
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administered via facemask, and further analgesia was provided if necessary 
with up to 4 boluses of 250 µg of alfentanil.  Continued discomfort 
necessitated conversion to general anesthesia.  After delivery, 3 units of 
oxytocin were administered IV during one minute. 
Time intervals noted were: time from arrival in theatre until injection of 
bupivacaine, time to T4 sensory block level, bupivacaine injection to skin 
incision time, bupivacaine injection to uterine incision time, uterine incision to 
delivery time, and skin incision to closure time. 
Blood loss was estimated by measurement in a graded suction bottle, 
and by observation of swabs.  Time to regression to T6 of block height 
as assessed by cold sensation, and to T10 as assessed by touch, was 
measured in recovery room. 
Calculation of sample size 
The null hypothesis was that a subarachnoid injection of bupivacaine 10 mg 
and fentanyl 10 µg would exert similar haemodynamic effects as indicated by 
equivalent vasopressor requirements to maintain mean arterial pressure 
within the stated limits in the two groups.  We assumed that a mean difference 
between the total phenylephrine doses at 30 minutes of less than 200 µg 
(standard deviation of 200 µg) would denote equivalent doses.  In order to 
demonstrate equivalent phenylephrine doses, sample sizes of 21 per group 
would be required.6 In addition, according to clinical experience, subarachnoid 
injection of hyperbaric bupivacaine 10 mg and fentanyl 10 µg as described 
above, usually produces sensory block up to the T3 dermatome (range T1 to 
T5).  We regarded an increase of one dermatome in block height in the obese 
group as clinically important (for example up to the T2 dermatome [range C8 
to T4]).  For similar power and alpha as for vasopressor requirement, 16 
patients per group were required‡.  In order to allow for greater than 
anticipated variability in vasopressor requirement, 50 patients were studied. 
‡ Medcalc Statistical Software, version 12.3.0.0 (MedCalc Software, Mariakerke, Belgium). 
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Statistical analysis 
Data were analysed using Medcalc Statistical Software (version 14.12.0, 
MedCalc Software, Ostend, Belgium).  Preliminary analysis of interval data 
included testing for normal distributions (D'Agostino-Pearson test) and 
equality of variances between groups (F-tests).  Two-tailed t-tests for 
independent samples were used to evaluate mean differences between 
groups.  If the sample data did not meet the criteria for parametric tests 
(normal distribution and equivalent variances), Mann-Whitney-U-tests were 
performed.  95% Confidence intervals between medians were estimated using 
Confidence Interval Analysis software (version 22.0, build 57, Trevor Bryant, 
University of Southampton).  Correlations were sought by calculating 
Pearson’s product moment correlation coefficient for interval data and 
Spearman’s rho for ordered categorical data. A P value d 0.05 was regarded 
as indicating statistical significance. 
Results 
All of the 50 recruited patients completed the trial without any protocol 
violations.  Demographic data are presented in Table 1.  All participants in the 
Group O were morbidly obese (BMI range 41-61 kg.m-2 vs 21-31 kg.m-2 in 
Group N).  The weights ranged between 111-160 kg vs 51-96 kg.  The Group 
O patients were statistically significantly older (mean [SD] 30.4 [6.0] years, vs 
27.1 [5.3]).  No differences were found in baseline mean- and diastolic blood 
pressures.  Group O patients had statistically significantly higher average 
systolic [SD] arterial blood pressures (130.5 [19] mm Hg, vs 121.2 [13] mm 
Hg). 
Primary outcomes were as follows: 
i. Vasopressor requirement:
There were no significant between-group differences in vasopressor use at 30
minutes (median [interquartile range]) (150 [0-400] vs 100 [50-600] µg for
Group N and Group O respectively.  There were also no differences in total
phenylephrine dose (mean [SD]) (286 [314] vs 412 [469] µg respectively, or
during the pre-or post-delivery periods (Table 2, Figure 1).  In order to
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determine whether there were confounding variables that influenced 
vasopressor requirements, a one-way analysis of covariance was conducted 
with total phenylephrine dose as the dependent variable.  The factor was the 
groups and the dependent variables were age, blood loss, baseline systolic 
arterial pressure, time from uterine incision to delivery, and time from skin 
incision to skin closure.  None of these variables influenced phenylephrine 
consumption significantly.  There were only 3 patients in Group N and 4 in 
Group O who received ephedrine (p = 1.0), and the doses were similar.  
Blood pressure control was similar in the two Groups (Figure 2).  
ii. Assessment of upper limits of sensory block:
A summary of block height changes appears in Table 3.  There were no
significant between-group differences in block height as assessed by touch at
5- or 25 minutes, or temperature at 5 minutes.  At 25 minutes after spinal
injection, the median [range] dermatome height for loss of temperature
sensation was significantly higher in the Group O than in Group N (T2 [T1-
T4]) vs T4 [T2-T4]); 95% CI of the difference between medians 0 to 2
dermatomes (Figure 3).
Secondary outcomes were as follows: 
i  Hand-grip strength: 
No difference between groups could be demonstrated with regard to the 
median percentage changes in handgrip strength (Table 3).  The data were 
widely scattered.  Three patients had blocks extending to T1 for temperature, 
of whom two revealed no change in handgrip strength and the other a 
decrease of 30%. 
ii  Peak flow rate: 
No difference between the groups could be demonstrated with regard to the 
median percent reductions in peak flow (Table 3).  The data were widely 
scattered and there was no correlation between percent change in peak flow 
and dermatome height for either temperature or touch. 
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iii  Block regression: 
The mean time for regression of loss of touch sensation to T10 was 
significantly longer in Group O (152 vs 132 minutes, 95% CI of the difference 
between means 3.8 to 36.2 minutes) (Table 3). 
iv  Other pertinent time intervals: 
There were no differences in the mean times taken from arrival in the 
operating theatre until induction of SA, the time from induction to skin incision, 
or induction to uterine incision.  The uterine incision to delivery time was 
greater in Group O (62 s vs 45 s, 95% CI of the difference between means 3 s 
to 47 s), as was mean time taken from skin incision to skin closure (49 vs 39 
minutes, 95% CI of the difference between means 2 to 18 min).  Mean blood 
loss was greater in Group O (600 mL vs 450 mL, 95% CI of the difference 
between means 0 to 300 mL) (Table 4). 
v  Adequacy of analgesia:  
No patients required analgesic supplementation or conversion to general 
anesthesia. 
vi  Neonatal outcome:  
There were no differences in Apgar scores or neonatal cord gas values (Table 
4). 
Discussion 
The dose of hyperbaric bupivacaine for SA for CS in obese patients remains 
controversial.  Considering that the 95% confidence interval of the difference 
between the mean phenylephrine doses required to maintain stable blood 
pressures (-150 µg to 100 µg) was within the pre-defined exclusion interval of 
-200 µg to 200 µg (Figure 1), we can conclude that subarachnoid injection of
bupivacaine 10 mg and fentanyl 10 µg exerted similar haemodynamic effects
in patients with a BMI > 40 kg.m-2 and those whose BMI is < 32 kg.m-2.
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Sensory testing, using the modalities of touch and temperature to indicate the 
extent of anesthesia, showed that at 25 minutes after induction of SA, the 
median dermatome height for loss of temperature sensation was statistically 
significantly higher in Group O than in Group N, with a 95% CI of the 
difference in medians of 0 to 2 dermatomes.  However the clinical importance 
of this difference is uncertain, as there were no physiological consequences 
resulting from the generally higher temperature block, which is not surprising 
considering that the 95% confidence interval of the differences in block height 
(0-2) included both zero difference and a clinically important difference. 
The decision to use two modalities to assess the onset and extent of 
anesthesia was influenced by a publication which showed that single modality 
assessment of block height for CS, in particular touch, may erroneously 
indicate inadequate anesthesia.7  The Neuropen filament has been shown to 
be equivalent within one dermatome to ethyl chloride in the assessment of 
touch; hence ethyl chloride was used for the assessment of both modalities, 
after discussion with the senior author of this paper (IR).8  
One review has cautioned against the use of low dose SA for CS in normal 
BMI patients, in view of the risk of inadequate anesthesia.9  In non-obese 
parturients the ED50 and ED95 for hyperbaric bupivacaine with opiate has 
been shown to be 7.6 mg and 11.2 mg respectively.10  The authors also 
caution against dose reduction for hyperbaric bupivacaine for SA.  A recent 
meta-analysis suggests that any reduction of the bupivacaine dose to less 
than 8 mg with opiate, during single shot SA in the non-obese population, 
results in significantly increased requirement for analgesic supplementation 
(risk ratio = 3.76, 95% CI = 2.38 to 5.98, P< 0.001), and could result in 
conversion to general anesthesia.2 The dermatomal block height ranged 
between T2 – T6; however, there was no uniformity in the assessment method 
used.   
Studies investigating the relationship between patient BMI and block height in 
obstetrics are limited and show conflicting results.  Norris et al. showed no 
correlation between the height of sensory block and patient BMI.11  In this 
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study, morbidly obese patients were not included, and a fixed dose of 
hyperbaric bupivacaine was used.  Harten et al. concluded that adjusting the 
SA dose regimen for caesarean section according to the patient weight and 
height, results in less hypotension and fewer blocks above the T1 dermatome 
level.12  They randomised patients with weights 50- to 110 kg, and heights 
140- to 180 cm, to receive either a fixed dose of 12 mg hyperbaric
bupivacaine and 0.4 mg diamorphine, or an adjusted dose using a chart
taking height and weight into account.  The adjusted dose group received a
median [IQR] dose of hyperbaric bupivacaine of 9.5 [9-10] mg.  In the fixed
dose group, six patients experienced loss of sensation to pinprick above the
T1 dermatome, and three patients to C7 and C8, but no patients required
ventilatory support.  Some patients in the adjusted dose group required
supplementation of analgesia, suggesting that adjusting the dose according to
patient weight may result in inadequate anesthesia.  The use of dose charts is
not common practice at our institution and clinical experience involving
approximately 10,000 spinal anesthetics for CS per annum, is that 12 mg is
too high a subarachnoid dose for our patient population, while 9 mg increases
the possibility of maternal discomfort requiring analgesia supplementation.
It has been postulated that there may be increased cephalad spread of local 
anesthetic in obese parturients, due to decreased cerebrospinal fluid 
volume.13  This is possibly attributable to increased intra-abdominal pressure 
and/or raised epidural venous pressure and compression of the intrathecal 
space.14  Vertebral column length has also been suggested as an important 
variable with regard to local anesthetic spread within the subarachnoid space, 
but no formal correlation has been shown.15   
An early investigation showed a tendency towards higher cephalad spread, 
and more rapid onset and recovery from anesthesia, in obese non- pregnant 
patients receiving isobaric intrathecal bupivacaine, compared with patients 
with a normal BMI.16  However, Lee et al. found the ED95 for intrathecal 
hyperbaric bupivacaine in obese parturients to be 12.9 mg (95% CI 11.5 – 
34.8 mg), which was similar to that in non-obese patients.4  This study is 
limited by use of historical controls in whom the study protocol was different to 
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that used in the control group.  A further recent investigation, which is also 
limited by the use of historical controls, suggests that the ED95 for spinal 
bupivacaine with opiates in morbidly obese patients is 15 mg (95% CI 10.0 – 
20.0 mg), which is similar to that in non-obese patients.3  Morbidly obese 
patients (BMI ≥ 40 kg/m2) undergoing elective CS were randomly assigned to 
receive up to 11 mg intrathecal hyperbaric bupivacaine with opiates, and the 
ED95 was calculated from a logistic regression plot.  Even with this dose, 
which many would regard as considerable in obese patients, a similar 
incidence and severity of hypotension, and incidence of nausea and vomiting, 
was shown as in parturients with a normal BMI.  The authors concluded that 
morbidly obese- and non-obese parturients exhibit a similar response to 
modest doses of intrathecal hyperbaric bupivacaine.  They reported that the 
dose response in the obese population is variable, but recommended that 
doses less than 10 mg should not be used.  These findings support our 
hypothesis that the dose requirement for spinal bupivacaine for caesarean 
delivery should be similar in morbidly obese and non-obese patients.  Finally, 
a recent retrospective analysis suggests that high cephalad spread of 
bupivacaine is unlikely unless the BMI is greater than 50 kg.m-2.17  The mean 
(SD) BMI in our study was 51 (5.4) kg.m-2. 
In terms of secondary outcomes in the present investigation, it was not 
surprising that no between-group differences could be shown in hand grip 
strength after induction of SA, considering that no patient had a sensory block 
at or above the C8 dermatomal level.  A previous study comparing the effects 
of SA for CS on respiratory function in patients with a BMI > 30 kg/m2 and 
those with BMI < 25 kg/m2 showed that the obese patients had a greater 
reduction in respiratory function due to SA.  The median (IQR) values for vital 
capacity after SA were -24 (-16 to -21)%, versus -11 (-6 to -16)% 
respectively.18  In our study, which is the first to examine the effects of SA for 
CS on respiratory function in morbidly obese parturients, the between-group 
difference in decrease in peak flow rate was not significant (18.8- vs 19.7%).  
There was considerable variability in the data, evidenced by a wide range in 
percentage changes in both groups (Table 3). 
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The median time for regression of loss of touch sensation to T10 was 20 
minutes longer in Group O (Range 82-195 minutes in Group N vs 103-205 
min in Group O).  The increased mean duration of surgery in Group O (49 vs 
39 minutes), strengthens the conclusion that the dose of intrathecal local 
anesthetic should not be reduced in obese patients.  
Limitations of this study include the fact that it was not blinded, and that the 
sample size does not preclude possible outliers experiencing cervical 
dermatome blocks, that might be identified in a larger study.  However it is 
noteworthy that more than 1000 morbidly obese patients have received SA for 
CS at the Groote Schuur Maternity Centre using the same dose as in this 
study, in the past 3 years, with no patient requiring tracheal intubation due to 
high motor block.  Finally, our results do not apply to patients with extremely 
high BMI, in whom prolonged surgery is envisaged.  In these cases, combined 
spinal epidural-, continuous spinal-, or general anesthesia is required. 
In conclusion, despite the statistically significantly higher median dermatome 
height for loss of temperature sensation in Group O, we can conclude that an 
intrathecal dose of bupivacaine 10 mg and fentanyl 10 µg resulted in clinically 
equivalent effects in two groups of parturients with widely differing BMI, 
considering that there were no clinically important consequences.  In 
particular, vasopressor requirements were similar, as were the decreases in 
mean peak flow rate.  Notably the affected dermatomes did not extend to the 
innervation by the cervical nerve roots in either group.  Therefore, also in view 
of the possibly increased time to regression of the block and the longer 
surgical time in Group O, we conclude that the dose of intrathecal local 
anesthetic for single shot SA for CS should not be reduced in morbidly obese 
patients.  This is of special importance in low resource environments where 
combined spinal-epidural anesthesia is not routinely available, and the 
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Table 1: Demographic data 
Group 










percentiles p 95% CI Diff 
Age (years) 27.1 5.3 30.4 6.0 0.0437 0.1 to 6.5 
Weight (kg) 73.2 8.5 130.4 12.8 < 0.0001 51.1 to 63.4 
Height (cm) 162.8 6.8 160.1 5.0 0.1263 -6.1 to 0.8
BMI (kg.cm-2) 27.5 2.6 51.1 5.4 < 0.0001 21.2 to 26.0 
Baseline peak 
flow (L.s-1) 
360 60 341 48 0.225 -50 to 12
Baseline 
handgrip (kg) 
27.3 4.7 28.0 4.8 0.6146 -2.0 to 3.4
Gestational 
age (weeks) 
39 39 to 40 39 39 to 39 0.2379 0.0 to 1.0 
SAP (mmHg) 121.2 13.0 130.5 19.0 0.0497 0.01 to 18.5 
MAP (mmHg) 89.4 13.0 92.2 13.3 0.4496 -4.7 to 10.3
DAP (mmHg) 68.6 13.3 69.3 12.1 0.8504 -6.5 to 7.9
SD = standard deviation; 95% CI Diff = 95% confidence interval of the 
difference between the means or the medians;   Percentiles = 25th to 75th 
percentile;   SAP = baseline systolic arterial pressure;   MAP = baseline mean 
arterial pressure;     DAP = baseline diastolic arterial pressure; p = p-value for 
t-test or Mann-Whitney-U-test.
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Table 2: Vasopressor usage at various intraoperative stages 
Percentiles = 25th to 75th percentiles; 95% CI Diff = 95% confidence interval of 
the difference between the medians;    p = p-value for Mann-Whitney-U-test or 
for t-test for independent sample. 
Group N: BMI 21-31 kg.m-2, Group O: BMI 41-61 kg.m-2
Group 









percentiles Range p 
95% 
CI Diff 





Phenylephrine post-delivery (µg) 100 0 to 263 0 to 550 50 0 to 250 
0 to 
750 0.8417 0 to 0 
Total phenylephrine at 30 
minutes (µg) 150 0 to 400 
0 to 










Ephedrine pre-delivery (mg) 0 0.0 to 0.0 0 to 12.5 0 0.0 to 0.0 0 to 20 0.9703 0 to 0 
Ephedrine post-delivery (mg) 0 0.0 to 0.0 0 to 17.5 0 0.0 to 0.0 0 to 20 0.4693 0 to 0 
Total ephedrine at      30 min 
(mg) 0 0.0 to 0.0 0 to 30 0 0.0 to 0.0 0 to 20 0.9193 0 to 0 


































































































































































































































































































































































































































































































































































































Table 4:  Pertinent time intervals and neonatal outcome 
SD = standard deviation;  95% CI Diff = 95% confidence interval of the difference between 
the means or the medians;    Percentiles = 25th to 75th percentile;   p = p-value for t-test or 
Mann-Whitney-U-test;  insertion = insertion of spinal needle into subarachnoid space; APGAR 











p 95% CI Diff 
Arrival to induction of SA (min) 15 13.8 to 15.3 17 10.8 to 25.0 0.0831 -10 to 0.0
Insertion to skin incision (min) 16.6 6.2 14.2 4.3 0.1316 -5.4 to 0.7
Insertion to uterine incision (min) 21.7 6.9 23.5 8.1 0.4020 -2.5 to 6.1
Skin incision to skin closure (min) 39.4 11.9 49.1 15.9 0.0180 1.7 to 17.7 
Uterine incision to delivery (s) 45 30 to 95 62 45.0 to 142.5 0.0217 -47 to -3
Blood loss (mL) 450 400 to 563 600 450 to 850 0.0195 -300 to 0
APGAR (at 1 minute) 9 8 to 9 9 8 to 9 0.7108 0 to 0 
APGAR  (at 5 minutes) 10 9 to 10 10 9.8 to 10.0 0.4982 0 to 0 
UV pH 7.34 7.3 to 7.4 7.34 7.30 to 7.35 0.3706 -0.02 to 0.04
UVPCO2 (kPa) 5.75 5.3 to 6.4 5.85 5.2 to 6.3 0.8690 -0.45 to 0.40
UV PO2 (kPa) 3.1 0.8 3.4 0.8 0.2272 -0.2 to 0.8
UV bicarbonate (mmol/L) 22.1 19.9 to 23.6 21.8 20.6 to 22.6 0.5220 -0.7 to 1.5







































































Legends to figures: 
 
Figure 1: Total phenylephrine dose for the two groups.  The square markers 
depict mean values, the error bars, 95% confidence intervals of the mean 
values.  Group N: BMI 21-31 kg.m-2 Group O: BMI 41-61 kg.m-2 
 
 
Figure 2: Graph of mean arterial pressures of the two groups during the first 
30 minutes of spinal anesthesia.  The markers depict mean values and the 
error bars indicate the 95% confidence intervals of the mean values.  Group 
N: BMI 21-31 kg.m-2, Group O: BMI 41-61 kg.m-2 
 
Figure 3: Box and Whisker plot of block height for temperature sensation for 
the two groups.  The square markers depict the median values.  Group N: 
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Patient information sheet 
Spinal anaesthesia is a technique for injection of medication into the fluid 
around your spinal cord for the purpose of making the lower part of your 
torso and legs numb to make it possible to do your caesarean section.  
It is the preferred mode of anaesthesia for caesarean section and is 
safer than general anaesthesia, which involves putting you into a deep 
sleep. 
Prior to the injection, an intravenous line will be inserted in your arm.  
We would like to assess the height of the numbness following the 
injection, using the same dose of local anaesthetic, 10 mg, regardless of 
your weight.  Also, one of the possible side effects of spinal anaesthesia 
is a temporary drop in your blood pressure with associated dizziness, 
nausea and vomiting.  We would like to monitor your blood pressure so 
as to detect any changes, and we can treat a decrease in your blood 
pressure by injecting some medication via your intravenous line to 
restore your blood pressure.  We will record the total dose of medication 
used. 
 
Should you decide not to enter the study, your treatment will be of the same 
high quality that you would receive if you entered the study.  You can 
withdraw from the study at any time, and the doctors will continue your 
















Prospective Research Subject: Read this consent form carefully and ask as 
many questions as you like before you decide whether you want to participate 
in this research study. You are free to ask questions at any time before, 




The influence of body mass index on sensorimotor block and 





Principal Investigator: Dr. C. Ngaka 
Department: Anaesthesia 
Location: D23 NGSH 
Phone: 02104045003 
 
You are being asked to participate in a study designed to compare the effect 
of using the same dose of spinal bupivacaine 10mg, plus fentanyl 10μg 
regardless of your weight. 
 
Spinal anaesthesia is a technique for injection of medication into the fluid 
around your spinal cord for the purpose of making the lower part of your 
torso and legs numb to make it possible to do your caesarean section.  It 
is the preferred mode of anaesthesia for caesarean section and is safer 
than general anaesthesia, which involves putting you into a deep sleep.  
Prior to the injection, an intravenous line will be inserted in your arm.  
We would like to assess the height of the numbness following the 
injection, using the same dose of local anaesthetic, 10 mg, regardless of 
your weight.  We will again assess the height of the numbness at 
completion of the operation.  Your participation in the study will end 
when you are discharged from the post anaesthesia recovery room and 
you will not be expected to take any extra time off work. 
 
 One of the possible side effects of spinal anaesthesia is a temporary 
drop in your blood pressure with associated dizziness, nausea and 
vomiting.  We would like to monitor your blood pressure so as to detect 
any changes, and we can treat a decrease in your blood pressure by 
injecting some medication via your intravenous line to restore your blood 
pressure.  We will record the total dose of medication used. 
 
Your participation in this study will not provide any added benefit as it is 
standard of care for patients undergoing caesarean section. It will, 
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however, help improve the current practice in ensuring the safe 
management of anaesthesia to mothers regardless of their weight. 
 
Your identity in this study will be treated as confidential. The results of 
the study, including laboratory or any other data, may be published for 
scientific purposes but will not give your name or include any identifiable 
references to you. 
 
Should you decide not to enter the study, your treatment will be of the same 
high quality that you would receive if you entered the study.  You can 
withdraw from the study at any time, and the doctors will continue your 
management in the usual way.  
 
The Principal Investigator will answer any further questions you have about 
this study:  
Name:  Dr. Christian Ngaka 
Phone Number: 076 468 7134 
Any questions you may have about your rights, as a research subject will be 
answered by:  
Name: Professor M. Blockman 
Phone Number:  (021) 406 6411 
In case of a research-related emergency, call:  
076 468 7134 (day or night) 
 
 
I…………………………………….. have read and understand this consent 
form, and I volunteer to participate in this research study.  I voluntarily choose 
to participate, but I understand that my consent does not take away any legal 
rights in the case of negligence or other legal fault of anyone who is involved 




Name of person obtaining consent:…………………………. 
 
Signature:  ………………………………………. 
 
Witness:   (1)……………………… 
 
                 (2)………………………… 
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initials, hospital numbers, dates of birth, or other protected health care 
information. Retain copies of your Institutional Review Board approval and 
documentation of written informed consent from each study subject. The editor 
or reviewers may request copies of these documents to address questions about 
Institutional Review Board approval and study conduct. 
 
Anesthesia & Analgesia fully supports the Guidelines for Personal Patient 
Information set forth by Lippincott, Williams, and Wilkins (LWW). The LWW 
guidelines can be downloaded from http://journals.lww.com/nsca- 
jscr/Documents/New_Guidelines_for_Personal_Patient_Information_2.pdf 
 
Key elements of this policy include: 
 
 Photographs with bars placed over eyes of patients should not be used. If they 
are 
submitted, permission from the patient must be documented. 
 Only specific details about the subject that are essential for understanding and 
interpreting the results of a study, a specific case report, or case series should be 
provided. 
 Authors and editors should not alter or falsify details in case descriptions to 
provide 
anonymity because doing so may introduce false or inaccurate data into the 
medical 
literature. 
 Previous publication of patient information or news coverage of a case does 
not 
eliminate a patient’s right to privacy and does not negate the need for patient 
consent for use of any patient identifying information. 
 If “deidentification” is not possible, the editors will ask the author to obtain 
consent 
from the patient. If the patient cannot be located or refuses to consent to 
publication of the identifying information, the manuscript will not be published. 
Should this situation arise, the corresponding author and the Section Editor 
should discuss the possibility of deleting the identifying information prior to 
peer review. 
 In the event that the patient cannot provide consent due to death or legal 
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incompetency (this includes photos of cadavers), permission from the power of 
attorney is needed as well as proof of power of attorney. 
 If the patient is a minor, a legal guardian must provide consent. 
 
Investigational Drugs 
The Editorial Board of Anesthesia & Analgesia may exercise judgment about the 
ethics of a clinical trial involving investigational drugs that differs from the view 
of the investigator’s Institutional Review Board. This situation most frequently 
occurs in studies 
involving neuraxial or perineural drug administration, drug studies in children, 
and nonconformity in dose, route, or indication (“off-label” use). 
 
Neuraxial or Perineural Drug Administration 
Studies using drugs injected into the neuraxial (caudal, intrathecal, or epidural) 
or perineural space must meet at least one of three criteria: 
1. The drug is approved for neuraxial or perineural administration by the United 
States Food and Drug Administration (FDA) or the equivalent regulatory agency 
for the country in which the study took place. 
2. The drug is not approved for neuraxial or perineural use, but it is widely used 
and accepted for neuraxial (e.g., fentanyl) or perineural administration. The 
publication of dosing guidelines in multiple textbooks represents a reasonable 
demonstration that a drug is widely used and accepted for neuraxial or 
perineural administration. 
3. The study is performed under an Investigational New Drug (IND) or Biologics 
License Application (BLA) application approved by the FDA or the equivalent 
agency in the investigator’s country. Investigators in the United States are 
directed to the FDA website for further information on obtaining an investigator 
IND.b To obtain an investigator IND, the investigator must complete forms 1571 
and 1572 which are mailed to the FDA along with the investigator’s curriculum 
vitae. Should the investigator’s country not have an equivalent process, the 
investigator must submit a statement from the Institutional Review Board that 
the preclinical toxicity data were reviewed for safety by a qualified expert before 
approval of the human trial. 
 
The status of drugs for neuraxial or perineural administration can be found at 
http://www.aaeditor.org/Neuraxial.Perineural.Drugs.xls. Questions about this 
list, or about proposed studies of neuraxial or perineural drugs, should be 
addressed to the Editorial Office at editor@anesthesia-analgesia.org. Anesthesia 
& Analgesia will not publish a retrospective paper involving neuraxial or 
perineural drug administration if the treatment would be considered 







Drug Studies in Children 
Anesthesia & Analgesia is committed to expanding knowledge of the clinical 
pharmacology of drugs in children. However, studying drugs in children when 
there is no pediatric indication poses ethical concerns.2 Therefore, studies of 
drugs in children must meet at least one of three criteria: 
Updated October 2015 
1. The drug is approved for pediatric administration by the FDA or an equivalent 
regulatory agency. 
2. The drug is not approved for use in children but is widely used and accepted 
for pediatric administration. A reasonable demonstration that the drug is 
clinically accepted for use in children is when the administration in the study is 
consistent with the route, dose, and indication reported in multiple textbooks. 
3. The study is done under an IND application approved by the FDA or the 
equivalent agency in the investigator’s country, as described by Schultheis et al.3 
Investigators in the United States are directed to the FDA website for further 
information on obtaining an investigator IND.b 
 
Anesthesia & Analgesia will not publish a paper describing retrospective 
assessment involving pediatric drug administration if the treatment would be 
considered inappropriate or unethical in a prospective trial. 
 
Nonconformity in Dose, Route, or Indication (“Off-Label” Use) 
In the United States, FDA regulations state that drug use conforms to the package 
insert (“on-label”) when the dose, route of administration, and indication match 
the guidelines in the package insert. If the dose, route, or indication does not 
match the package insert, then the drug use is “off-label.” Drugs are commonly 
used off-label in clinical trials, and the practice is generally acceptable. However, 
the Editorial Board of Anesthesia & Analgesia reserves the right not to review a 
manuscript describing off-label administration of a drug if the Editorial Board 
believes the study posed unacceptable risk to subjects. To preclude such a 
determination, investigators are encouraged to obtain an Investigator IND from 
the FDAb or an equivalent agency in their country before initiating studies 





















Manuscripts describing investigations performed in vertebrate animals must 
explicitly state that the study was approved by the authors’ Institutional Review 
Board for animal research (e.g., the Institutional Animal Care and Use 
Committee). The Journal expects humane and ethical treatment of all 
experimental animals, and requires that the study has been conducted in a 
manner that does not inflict unnecessary pain or discomfort upon the animals, as 
outlined by the United States Public Health Service Policy on Humane Care and 
Use of Laboratory Animals and the Guide for the Care and Use of Laboratory 
Animals (1996), prepared by the National Academy of Sciences’ Institute for 
Laboratory Animal Research. A statement to this effect should appear at the 
beginning of the Methods section. 
 
Registration of Clinical Trials 
All clinical trials involving assignment of patients to treatment groups must be 
registered prior to patient enrollment. The registry, registration number, 
principal investigator's name, and date of registration must be stated in the first 
paragraph of the Methods section of the manuscript. A number of registries have 
been approved by the International Committee of Medical Journal Editors 
(http://www.icmje.org/faq_clinical.html)including http://www.clinicaltrials.gov 
(the most commonly used registry in the United States), http://isrctn.org, 
http://www.umin.ac.jp/ctr/index/htm,http://www.anzctr.org.au,and 
http://www.trialregister.nl. Submissions that have registered with the European 
Clinical Trials Database, EudraCT (https://eudract.ema.europa.eu/) meet this 
requirement. 
 
CONFLICT OF INTEREST 
A conflict of interest exists when an author’s judgment about a manuscript may 
be influenced by secondary gain. Secondary gain typically involves personal, 
financial, academic, or political advancement. Examples of financial gain are 
easiest to identify and include direct monetary benefits, such as investments, 
stocks, honoraria, etc. When study results (as differentiated from publication per 
se) may affect an author’s bonus, incentive payment (e.g., from likely changes in 
clinical workload), or salary (e.g., research about academic appointments and 
salary), this is also considered a conflict of interest. Academic recognition and 
advancement resulting from publishing high quality papers are the appropriate 
reward for good work and do not represent a conflict of interest. 
Potential conflicts of interest in addition to actual conflicts of interest also 
commonly occur and must be considered. In some disciplines they may be 
unavoidable. Authors of scientific studies sponsored by industry possess a 
conflict of interest. Authors employed by a company with a commercial interest 
in the outcome of a study also possess a conflict of interest. Although these 
conflicts are understood and accepted, they must be disclosed. Investigators may 
have consulting or lecturing relationships with companies sponsoring their 
research. These relationships may be entirely appropriate, but they must be 
disclosed. Conflicts of interest must be disclosed on initial submission for every 
author. Disclosure is required for every manuscript, including Editorials and 
Letters to the Editor. Disclosures are reviewed by the handling editor so that a 
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decision can be made on whether competing interests may have influenced the 
manuscript in any manner. A manuscript will not be rejected solely because of 
conflicts of interest. Disclosures are available to reviewers during peer review, 
and are included when the manuscript is published. 
Conflicts of interest must be disclosed on every title page whether created 
through the Title Page Generator (http://www.aaauthor.org) or our Title Page 
template (http://edmgr.ovid.com/aa/accounts/ifauth.htm). This title page must 
appear at the beginning of the manuscript. 
Anesthesia & Analgesia does not have a threshold monetary value to determine 
“relevant” or “significant” conflicts of interest. The Journal does not have a 
threshold period of time after which a potential conflict of interest ceases to 
exist. All relevant potential conflicts of interest should be declared regardless of 
monetary value or the date of the relationship. Conversely, extensive disclosures 
of irrelevant or ancient relationships may unintentionally obfuscate relevant 
conflicts. 
Authors are encouraged to err on the side of full disclosure. Full disclosure at the 
time of submission has fewer repercussions than subsequent exposure of a real 
or potential conflict. Authors are encouraged to contact the Editorial Office at 
editor@anesthesia-analgesia.org if they have questions about whether specific 
conflicts of interest should be disclosed. 
 
PREPARING YOUR MANUSCRIPT 
The following pages describe the types of manuscripts published by Anesthesia & 
Analgesia. The guidelines offer general rules on length, format, and content. 
These guidelines are intended to help authors write manuscripts meeting the 
expectations of reviewers and editors, improving chances that a manuscript will 
be accepted for publication. If a manuscript must deviate from these guidelines 
in any significant manner, please contact the Editorial Office at 
editor@anesthesia-analgesia.org before submitting the manuscript to be certain 
that the Journal will consider publication. Additionally, please explain any 
significant deviations from the expected format in the “Enter Comments” section 
when submitting your manuscript via Editorial Manager. 
Submissions to Anesthesia & Analgesia should use grammatically accurate 
English with American spellings. Authors not fluent in English are encouraged to 
write their submissions in their native language. After fully vetting the 
manuscript in their native language, authors can hire a professional service to 
translate the manuscript into scientific English prior to submission. Professional 
translation services should be acknowledged in the manuscript. Individual 
translators should be named either as an acknowledgment or, in exceptional 
circumstances, as coauthors. All accepted submissions will be edited for syntax, 
grammar, and spelling. 
 
Manuscript Types and Word Count 
Please review the following descriptions of manuscript types and recommended 
word counts. Word counts are included for guidance. They are not strictly 
enforced. Manuscripts should be as succinct as possible. All submissions must 
include a title page created either through the Title Page Generator 





Research Reports describe original clinical or laboratory investigations. A meta-
analysis of a series of research papers is also a Research Report. Research 
Reports include a structured Abstract typically less than 400 words, an 
Introduction (typically less than 500 words, e.g., 1 page), Methods, Results, and 
Discussion (typically less than 1500 words, e.g., 3 pages). Research Reports are 
typically less than 3000 words (excluding supplementary online data). 
A meta-analysis is a formal statistical analysis of an existing body of literature 
with the intention of producing new knowledge. A meta-analysis should be 
written and submitted as a Research Report, not as a Review Article. 
Anesthesia & Analgesia is among the most selective journals in our discipline. 
Accepted Research Reports use state-of-the art tools in study design, data 
collection, and statistical analysis. Accepted reports typically provide novel 
information to improve patient care or increase our understanding of 
fundamental mechanisms. 
 
Research Reports may be rejected without peer review if the question is not 
interesting, the results are inconclusive, the results could be predicted as logical 
extrapolations of existing knowledge, the methodology is inappropriate to the 




As of November 15, 2012, Anesthesia & Analgesia will no longer accept Case 
Report submissions. Case Reports will be reviewed and published in the online 




Echo Rounds are brief reports providing a focused discussion of one or more 
unique or interesting perioperative echocardiographic image (transesophageal, 
precordial, epicardial, or epiaortic) from a clinical situation in which 
echocardiography was central to clinical management. Submissions should 
provide succinct points on echocardiographic views, techniques, or calculations. 
Only relevant clinical details should be presented. Echo Rounds are not “Mini 
Case Reports” because they include far less clinical detail than Case Reports. 
The suggested format is to present clinical details and specific echo findings in 
the first third of the report and didactic discussion of the echo topic(s) in the 
subsequent two-thirds followed by no more than 7 references. The report should 
be accompanied by no more than 3 echocardiographic still images and 3 video 
clip(s), with legends, which will be available online. The still images should 
usually, but not always, correspond to the respective video clip(s). Authors 
should provide appropriate labeling (e.g., arrows, abbreviations of anatomic 
structures, etc.) of figures and video clips (if possible) and may elect to 
consolidate consecutive time segments into one clip (although adequate viewing 
time for each segment must be provided to clearly illustrate the primary findings 
being discussed in the text). Selected reports may benefit from the addition of a 
brief table or schematic figure. Authors are advised to examine previously 
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published Echo Rounds (either via the Table of Contents or via the online Echo 
Rounds database at http://www.scahq.org or via www.anesthesia-analgesia.org) 
to avoid submission of topics previously published in this series. See page 29 for 
video formatting details. Echo Rounds do not include an Abstract and are 
typically less than 1100 words in length. 
Consent 
Echo Rounds about one or more patients must include a statement that the 
patient and/or the patient’s family reviewed the report and gave written 
permission for the authors to publish the report. At least one author must have 
participated in the care of the patient described in the case report. Please include 
your consent statement at the beginning of your report. 
In cases where neither the patient nor any family member can be contacted due 
to certain circumstances (e.g., patient death), and the local IRB has determined 
that review and written approval are unnecessary, a statement by the author 
explaining this circumstance may be acceptable if: 
1. The reported event(s) occurred more 3 years prior to submission of the 
report. In this circumstance, the year of the event(s), as well as a detailed 
explanation regarding why attempts to obtain written consent were 
unsuccessful, should be included in the cover letter. 
2. The patient(s) can be de-identified by removing obvious demographic 
information without compromising the scientific value of the report. The editors 
reserve the right to further delete or request additional information considered 
essential for complete understanding of the report. 
These standards will apply to both adult and minor patients. 
Retain copies of your documentation of written informed consent from each 
patient 
and /or the IRB approval and reasons for obtaining it. The editors or reviewers 
for Anesthesia & Analgesia may request copies of these documents at any time. 
Please DO NOT submit a copy of the written consent form unless it is specifically 
requested by the editors or reviewers. 
 
Checklist 
All Echo Rounds must also include a completed Echo Rounds Checklist. This 
checklist is available at http://edmgr.ovid.com/aa/accounts/ifauth.htm#Before. 
 
Echo Didactics 
Echo Didactics are solicited submissions presenting a practical clinical review of 
a particular echocardiographic topic (e.g., important measurements, specific 
anatomic evaluation, current or emerging technologies). Echo Didactics do not 
include an Abstract but should include a discussion of the relevant background, 
the “nuts and bolts” of assessment and measurement, and new concepts. Echo 
Didactics should include 1 to 3 figures or short tables, 1 to 3 video clips 
(composite videos, as described for Echo Rounds) and appropriate references 
(not to exceed 10). The author should provide 3 to 4 bulleted teaching points 
summarizing the most important teaching points. Echo Didactics are typically 
less than 1000 words. 
 
Brief Reports 
Brief Reports are intended to report clinical or laboratory research observations. 
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Brief reports are not appropriate for hypothesis-based research which should be 
reported as a Research Report. Brief Reports may be appropriate for studies 
reporting observations without formally testing a hypothesis. Brief Reports can 
also be used to provide initial reports of new technologies, or describe a novel 
pilot study. 
Brief Reports require an Abstract typically less than 100 words, which may be 
structured or unstructured depending on the topic. Brief Reports contain an 
Introduction, Methods, Results, and a very brief (1 paragraph) Discussion. Brief 
Reports are typically less than 1000 words. 
 
Technical Communications 
Technical Communications describe instrumentation and analytic techniques. 
Technical Communications include an unstructured Abstract, typically less than 
400 words, and the text of the communication, typically less than 1500 words. 
 
Review Articles 
Review Articles synthesize previously published material into an integrated 
presentation of current understanding of a topic. Review Articles should 
describe aspects of a topic in which scientific consensus exists, as well as aspects 
that remain controversial and are the subject of ongoing scientific disagreement 
and research. Review Articles are expected to be comprehensive in scope. If the 
author used a formal strategy to search the medical literature, this strategy 
should be described. Review Articles should include an unstructured Abstract 
typically less than 400 words. Review Articles are typically less than 5000 words. 
 
Medical Intelligence Articles 
Medical Intelligence Articles collate and evaluate previously published material 
to aid in evaluating new concepts or updating old concepts germane to 
anesthesiology. Medical Intelligence Articles are expected to be highly focused in 
scope. They should include an unstructured Abstract typically less than 100 
words, and the text of the review, which is typically less than 2000 words. 
 
Special Articles 
Special Articles are manuscripts not described by any of the above categories. 
They are typically invited by the Editorial Board to examine a particular topic. 
There are no word limits or rules for the structure of Special Articles. They may 
have a structured or unstructured abstract typically less than 400 words, or no 
abstract. 
Statements issued by organizations to guide clinical care (e.g., guidelines, 
practice parameters, recommendations, consensus statements, position papers) 
are published as Special Articles. Societies interested in publishing such 
statements in Anesthesia & Analgesia should contact the Editor-in-Chief at 
editor@anesthesia-analgesia.org to discuss the process of publishing guidelines 
in the Journal. Affiliate Societies should contact the appropriate Section Editor to 
discuss the role of the Journal in the process of publishing the guideline. The 
submission must describe the clinical problem to be addressed, the mechanism 
by which the statement was generated, a review of the evidence for the 
statement, if available, and the statement on practice itself. 
Occasionally more than one group or society will issue guidelines on the same 
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topic, resulting in confusion among clinicians.4 To minimize confusion and 
enhance transparency, guidelines published in Anesthesia & Analgesia should 
begin with the following 4 bulleted phrases, followed by brief comments 
addressing each phrase: 
 What other guidelines are available on this topic? 
 Why was this guideline developed? 
 How does this guideline differ from existing guidelines? 
 Why does this guideline differ from existing guidelines? 
 
Editorials 
Editorials provide perspective on articles published in the Journal or express the 
general policies or opinions of the Editorial Board. Editorials are solicited by the 




Pro/Con Editorials are scholarly discussions of clinically relevant topics 
providing opposing, well-founded viewpoints. They are solicited by the Editorial 




Pro/Con/Core Reviews present a focused Review Article accompanied by expert 
commentary for and against a specific clinical topic or technique. The Core 
Review Article includes an Abstract typically less than 100 words, and the text of 
the review which is typically less than 2500 words. It may be accompanied by 
figures or a video supplement. Pro/Con/Core Reviews are solicited by the 
Editorial Board. 
 
Book and Multimedia Reviews 
Book and Multimedia Reviews report current literature and apps in 
perioperative medicine, critical care, and pain management, as well as general 
scientific topics of interest to anesthesiologists. Publishers interested in having 
their book or multimedia material reviewed by the Journal should first contact 
our Media Reviews editor at bookreviews@anesthesia-analgesia.org before 
sending the material. Book Reviews, App Reviews, website or blog reviews (all 
encouraged) are typically less than 750 words. 
All contributors to Anesthesia & Analgesia are encouraged write reviews about 
books that our readership might find interesting. Authors interested in 
submitting a book review should contact our Media Reviews editor at 
bookreviews@anesthesia-analgesia.org to see if the editor believes the review 
would be of interest to readers of the Journal. 
 
Meeting Reports 
Meeting Reports are scholarly outlines of the program and content of a scientific 
meeting. They may be organized temporally (day by day) or thematically (topic 
by topic). Authors interested in submitting meeting reports should first contact 
our Media Reviews editor at bookreviews@anesthesia-analgesia.org to confirm 
that the meeting is of general interest to the readership. Meeting reports do not 
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have Abstracts and are typically less than 1500 words. 
 
Focused Reviews 
Focused Reviews summarize recent advances in a particular field with direct 
application to clinical practice. They are intended to efficiently communicate 
new knowledge to make clinical practice safer, more efficient, and up-to-date. 
They are solicited by the Editorial Board. Focused Reviews contain an 




Commentaries provide expert perspective on articles or topics published in the 
Journal. They are typically solicited from reviewers who provide unusually 
thoughtful insight during the peer review process that should be shared with the 
Anesthesia & Analgesia readership. They are solicited by the Editorial Board. 
Commentaries contain a title page, text and references and do not have an 
Abstract. They are typically less than 1500 words. 
 
The Open Mind 
The Open Mind is a forum for thoughtful, scholarly, and well-referenced reader 
perspectives. The Open Mind is intended to stimulate discussion. Submissions to 
The Open Mind must be intellectually rigorous. The Open Mind is not a forum for 
rants, tirades, or complaints about being overworked and underpaid.5 
Submissions to The Open Mind do not have an Abstract and are typically less 
than 1500 words. 
 
Letters to the Editor 
Letters to the Editor are submitted using Editorial Manager 
(http://aa.edmgr.com). Authors should consider the following points when 
composing a Letter to the Editor:6 
Consent 
Letters to the Editor about one or more patients must include a statement that 
the patient, the patient’s family, or the local IRB reviewed the Letter to the Editor 
and gave written permission for the authors to publish the letter. If such 
permission has not been obtained, this must be disclosed in the letter as well as 
the reason for not obtaining patient permission. A Letter to the Editor becomes a 
research study if the authors intended to publish the outcome at the time they 
provided treatment for the patient. The authors should obtain Institutional 
Review Board approval and written informed consent before treating the 
patient. If that is not possible then the author should obtain Institutional Review 
Board approval and patient consent to pursue publication shortly after providing 
treatment and in advance of submission to Anesthesia & Analgesia. 
 
Brevity 
Letters that respond to a published paper are typically less than 300 words. Long 
critiques are difficult to follow and will likely generate a response that is also too 
lengthy. Letters describing an interesting or uncommon clinical experience 
should be limited to relevant clinical details. Unlike Case Reports, letters that 
describe clinical care should not delve into the background of diseases or 
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therapeutic interventions. A letter describing a new gadget or technique should 
not exceed 3-5 paragraphs. References should be limited to a few key articles. 
Focus 
A letter should address a single issue, not an entire subject. The first sentence 
should identify the reason for submission (e.g., a flaw in methodology, relevant 
observations, or alternative explanation). A letter should be of interest to more 
than the correspondent and the author of the article in question. Quibbles 
involving a complex and sophisticated subject or methodology should be settled 
privately rather than in the Correspondence Section of the Journal. 
Scientific Accuracy 
Letters do not necessarily have the imprimatur of external peer review. 
Nevertheless, scientific accuracy is crucial. If letters deal with complex or arcane 
issues they will be peer reviewed by members of our Editorial Board and outside 
reviewers, especially when letters propose a new idea or methodology. 
 
Tone 
Letters must be respectful. Letters that attack authors, the Journal, or our 
readership will not be published. Letters that are self-promoting will not be 
published. Just as we discourage authors of peer-reviewed articles from claiming 
to be the first to make an observation, we similarly are not interested in letters 
claiming prior publication of an observation. We will publish letters to correct 




A letter written in response to a published paper should be submitted no later 
than 4 months after the paper has been published in print. A longer interval 
detracts from the interest, relevance, and impact. Letters responding to 
manuscripts published online are held, but not considered, until the manuscript 
appears in print. 
 
Writing 
All letters are edited, and occasionally completely rewritten, to be highly focused, 
readable, and succinct. Accepted letters may or may not be forwarded to the 
author to approve the edited text. 
 
Conflict of Interest 
Conflict of interest disclosure is required for all submissions to the Journal, 
including letters. 
All Letters to the Editor must include a Title Page in the style of our journal. 
Please use our Title Page template at: 
http://edmgr.ovid.com/aa/accounts/ifauth.htm#Before. 
 
GENERAL GUIDELINES AND SET-UP INSTRUCTIONS 
Authors are encouraged to follow these guidelines carefully to improve the 
timeliness and quality of the review process. The Editors of Anesthesia & 
Analgesia may return manuscripts to authors without peer review if the 
manuscripts do not conform to these guidelines. 
 Follow the specifications in Uniform Requirements for Manuscripts Submitted 
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to Biomedical Journals, as updated in 2010, available at http://www.icmje.org. 
 Carefully think through the overall organization of the manuscript. Follow the 
guidance given in the subsections below to prepare each section. 
 Write clearly. Be straightforward, unambiguous, and succinct. Strunk and 
White’s The Elements of Style7c provides excellent guidance on clear writing. 
 Follow the technical styles found in these texts: 
o Scientific Style and Format: The CSE manual for Authors, Editors, and 
Publishers. 7th ed.8 
o American Medical Association. Manual of Style, 10th ed.9 
 First-time authors will benefit by reading the unpublished "A Step by Step 
Guide to Writing a Scientific Manuscript" by Wenzel, Dünser and Lindner, at 
http://www.aaeditor.org/StepByStepGuide.pdf 
 Prospective randomized clinical trials should be presented in accordance with 
the CONSORT statement (http://www.consort-statement.org). The CONSORT 
statement includes general principles applicable to many types of investigations. 
Authors should complete and submit the CONSORT checklist when preparing 
their submission. 
 Prospective and retrospective observational trials should be presented in 
accordance with the STROBE statement (http://www.strobe-statement.org). 
Authors should complete and submit the appropriate STROBE checklist when 
preparing their submission. 
 Systematic reviews and meta-analyses should be presented in accordance with 
the PRISMA statement (http://www.prisma-statement.org). Authors should 
compete and submit the appropriate PRISMA checklist when preparing their 
submission. 
 Follow these rules when composing your manuscript: 
o Create your manuscript using Microsoft Word or a fully compatible 
program. 
o Use “Standard US Paper” or “Letter” page format (width of 8.5 inches or 
21.59 centimeters, length of 11 inches or 27.94 centimeters) for your 
manuscript before uploading the document to Editorial Manager. 
o Double-space all text, including references and table and figure legends. o 
Begin each section (title page, abstract, introduction, methods, results, 
discussion, acknowledgments, references, tables, and legends) on a new page by 
inserting a page break before each part. 
c See http://www.bartleby.com/141, last accessed May 28, 2012  
 
o Number pages consecutively in the upper right corner beginning with the title 
page. 
 Upon submission for all new submissions, we require each author to complete 
and sign a digital copyright assignment agreement uploaded into Editorial 
Manager (under “Attach Files”) by the corresponding author. We do not accept 
copyright assignment forms by fax or email. For more information visit: 
http://edmgr.ovid.com/aa/accounts/ifauth.htm. Please direct questions about 
copyright transfer to the Editorial Office at editor@anesthesia-analgesia.org. 
The Editorial Office has prepared templates in Microsoft Word format that 
should be downloaded and used for manuscript preparation 
(http://edmgr.ovid.com/aa/accounts/ifauth.htm). Each template includes the 
 77 
appropriate formatting defaults, instructions for the type of manuscript being 
submitted, and a checklist for manuscript submission. The instructions and 
checklist should be deleted before submitting the manuscript electronically. 








 Letters to the Editor 





 Statistical Grand Rounds 
 Technical Communications 
 The Open Mind 
Please download our Case Reports template 
(http://edmgr.ovid.com/aacr/accounts/ifauth.htm#Before) before submitting 
your Case Report for consideration to A&A Case Reports. For more information 





All submissions require a title page. Please create the title page of your 
manuscript by either using the Title Page Generator (http://www.aaauthor.org) 
or our Title Page template (http://edmgr.ovid.com/aa/accounts/ifauth.htm). 
With the Title Page Generator, a complete title page will be generated (as an RTF 
file), which you must copy and paste into your manuscript (typically a Microsoft 
Word document). The Title Page Generator efficiently gathers the necessary 
information for the title page. If you use the Title Page Generator you do not need 
to prepare a separate title page. 
Title pages must contain the following elements (Note: all elements are provided 
when using the Title Page Generator or Title Page template): 
 Title of the article: Be concise but informative. Include species when 
appropriate. 
 Short Title: An abbreviated title of no more than 60 characters including 
letters and spaces. The short title appears in the abbreviated table of contents in 
the Journal and 
also appears in the footer of the published article. 
 List of Authors: First name, middle initial, and last name of each author, with 
highest academic degree(s) (MD, PhD, etc) and an e-mail address for each 
author. Each author must: 
o Indicate his or her affiliation (Department, Institution/Company, City, 
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State/Country) at the time the work was performed. If the author has moved 
since the work was performed the current institution may appear in 
parentheses, e.g., (Current Affiliation: Department, Institution/Company, City, 
State, Country). 
o Disclose his or her contribution to the manuscript. Identified contributions 
include study design, conduct of the study, data collection, data analysis, and 
manuscript preparation, e.g., “this author helped design the study and prepare 
the manuscript.” 
o Attest to having approved the final manuscript, e.g., “Dr. Smith approved the 
final manuscript.” 
o For research reports, brief reports, and technical communications involving 
more than one author, at least two authors must attest to having reviewed the 
original study data and data analysis e.g., “Dr. Smith attests to the integrity of the 
original data and the analysis reported in this manuscript.” 
o One author must be designated as the archival author who is responsible for 
maintaining the study records, e.g., “Dr. Smith is the archival author.” 
o Disclose all conflicts of interest or indicate that no conflict of interest exists. 
All relationships between authors and any company or organization with a 
vested interest in the outcome of the study should be disclosed including both 
current and previous relationships. More information on conflict of interest can 
be found on page 9. 
 If two authors are to be considered “co-first authors” this should be identified 
as a footnote to each co-first author. The footnote will appear in the published 
paper, but does not appear in PubMed. 
 Authors who wish to change the authorship line during peer review should be 
prepared to explain the rationale for the change. Following acceptance of the 
manuscript the authorship line can only be changed with a written request to the 
Editor-in-Chief at editor@anesthesia-analgesia.org. 
 Name of Department(s) and Institution(s) to which the work should be 
attributed. Multiple institutions may be listed if appropriate. The National 
Library of Medicine (PubMed) determines institutional affiliation from the 
affiliation of the first author. Anesthesia & Analgesia has no control over this 
process. 
 
 Corresponding Author: Name, department, institution, full address, 
telephone number, and e-mail address of author responsible for manuscript 
correspondence. 
 Reprints: Name and address of author to whom requests for reprints should 
be addressed, or a statement that reprints will not be available from the author. 
 Funding Statement: The source(s) of funding, including foundations, 
institutions, pharmaceutical and device manufacturers, private companies, 
donors, or intramural departmental sources. Please also indicate if this work was 
funded by: National Institutes of Health (NIH), Howard Hughes Medical Institute 
(HHMI), Medical Research Council (MRC), and/or Wellcome Trust. 
 IRB Contact Information: For all studies involving human research, include 
the name and full contact information (Contact Name, Institution, Address, 
Phone, Email) for the Institutional Review Board that approved the study. 
Abstract 
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 The Abstract should appear after the title page(s). 
 Structured abstracts include Background, Methods, Results, and Conclusions. 
Structured abstracts should provide enough detail to permit the reader to 
quickly understand the study and findings. 
o Background: State the context and purpose of the research, and the 
hypothesis being tested. 
o Methods: Define the study subjects or experimental animals, study groups, 
controls, data collected, primary and secondary endpoint(s), and analytic and 
statistical methods. 
o Results: State the number of subjects studied, key findings, and statistical 
significance including confidence intervals. 
o Conclusions: State whether or not the hypothesis was proven, and the 
scientific and clinical conclusions drawn from the study. 
 Unstructured Abstracts summarize the article, including salient observations 
and conclusions. 
 Word Count: The table below suggests word limits for abstracts, based on 
manuscript type. Abstracts may modestly exceed the word limit if necessary. 
Table 1: Word Counts 
Updated October 2015 
Manuscript Type 
Abstract Type 
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The text of Research Reports is usually, but not necessarily, divided into the 
following sections: Introduction, Methods, Results, and Discussion. 
Introduction 
 Summarize the background in one or two sentences. 
 Offer only fundamental background information for the work. 
 Succinctly state the purpose of the study. 
 If the study tests specific hypotheses, state the hypotheses. 
 Do not review the topic. 
 The introduction is typically less than 500 words. 
Methods 
 Methods must be presented in sufficient detail that readers can understand 
how the results were obtained, and other investigators can replicate the study.10 
 State the study’s conformance with the Journal’s requirements for human and 
animal trials, as described in Ethical Conduct of Research, page 5. 
 If the study involves neuraxial or perineural drug administration, drug 
administration in children, or “off-label” use of drugs, please state how the study 
conforms to the Investigational Drugs guidelines on page 6. If the drug is used 
“off- label” and an investigator IND was not obtained, this should be stated. If an 
investigator IND was obtained please include the IND number. 
 If the trial is registered (see page 8) state the clinical trial registry, registration 
number, and date of registration. 
 Inclusion and exclusion criteria: describe how observational or experimental 
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subjects (patients or experimental animals, including controls) were selected. 
 Describe methods, materials, devices (manufacturer’s name and city, state, 
country in parentheses), computer software (including revision numbers), and 
procedures in sufficient detail so that the experiment can be reproduced by 
other investigators. If 
22 the text and the references cannot succinctly provide adequate detail, include 
an 
Appendix, or provide additional material as Supplemental Digital Content. 
 Disclose molecular structures when describing novel compounds. Structural 
disclosure may be waived at the discretion of the Editorial Board when there is a 
compelling reason to publish a manuscript before the sponsor is ready to 
disclose the molecular structure. 
 Provide references to established methods. 
 Provide references and brief descriptions for published methods that are not 
well 
known. The Methods section should be interpretable to a knowledgeable reader 
without requiring accessing another manuscript to understand to the methods 
used. 
 Describe new or substantially modified methods, give reasons for using them, 
and 
define their limitations. 
 Identify all drugs and chemicals including generic name(s), dosage(s), and 
route(s) 
of administration. Refer to the drugs throughout the text by their generic names 
unless the subject of the research is a comparison of branded formulations in 
which case the use of the brand name is more precise. 
 If you use a methodology that you previously reported it is appropriate to use 
wording identical to your previous wording. If you are not the author of the 
previous description of the methodology, then the methodology must be 
rewritten with reference to the original description of the methodology, or 
placed in quotation marks with a citation to the original description. 
 Present methodologies in the same order in which the results are presented. 
Statistical Methodology 
 Describe all data handling and statistical methods. 
 Clearly state the exact statistical test used for the primary hypothesis and all 
secondary hypotheses. 
 Conventional biostatistics, such as the T test, ANOVA, and Chi Square test, were 
developed more than 60 years ago. Statistical methodology has advanced since 
then. While these tests may still be appropriate, it is likely that additional 
statistical analysis will be required. Anesthesia & Analgesia has published a series 
of “Statistical Grand Rounds” and other statistically oriented papers to help 
authors understand our expectations of statistical methodology for different 
types of studies. 
 
Table 2: Statistical Guidance in Anesthesia & Analgesia 
 
If your study 
Then please review the statistical guidance in 
Includes learning curves 
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Learning curves and mathematical models for interventional ultrasound basic 
skills. Anesth Analg. 2008;106:568-7311 
Includes P-values but not confidence intervals 
Checklist for statistical topics in Anesthesia & 
Analgesia Reviews. Anesth Analg 2011;113:216- 912 
Has an intervention variable that was not randomized, such as choice of drug 
dose, but does not include propensity scores 
Checklist for statistical topics in Anesthesia & 
Analgesia Reviews. Anesth Analg 2011;113:216- 912 
Has a dependent variable that may differ among providers, such as physicians, 
but that dependent variable is not analyzed by stratification or mixed models 
Checklist for statistical topics in Anesthesia & 
Analgesia Reviews. Anesth Analg 2011;113:216- 912 
Includes an intervention applied for the patients of some but not all providers, 
some but not all facilities, etc. 
An introduction to multilevel modeling for anesthesiologists. Anesth Analg 
2011;113:877- 8713 
Has multiple observations measured over time 
Checklist for statistical topics in Anesthesia & 
Analgesia Reviews. Anesth Analg 2011;113:216- 912 
Uses meta-regression without complete study data 
Checklist for statistical topics in Anesthesia & 
Analgesia Reviews. Anesth Analg 2011;113:216- 912 
Has a primary or secondary endpoint that is either cost or time, but the endpoint 
has not been analyzed using methods suitable to estimate the mean of skewed 
data 
Checklist for statistical topics in Anesthesia & 
Analgesia Reviews. Anesth Analg 2011;113:216- 912 
Has included time to complete a task 
Analysis of variance of communication latencies in anesthesia: comparing means 
of multiple log- normal distributions. Anesth Analg 2011;113:888-9614 
Includes patient waiting times 
Analysis of interventions influencing or reducing patient waiting while 
stratifying by surgical procedure. Anesth Analg 2011;112:950-715 
If your study includes a survey 
Inconsistent survey reporting in anesthesia journals. Anesth Analg 2011;113; 
591-516 
Evaluates equivalence (inferiority), and is neither paired nor simply involves two 
groups 
Equivalence and noninferiority testing in regression models and repeated-
measures designs. Anesth Analg 2011;112:678-8717 
 
Includes analgesic consumption (e.g., total morphine received during first 24 
hours postoperatively) 
The influence of age on sample size calculation in acute pain trials using 
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morphine consumption as an end point. Anesth Analg 2010;110:1186- 9018 
If your study includes both analgesic consumption and visual analog scale for 
pain, or equivalents 
Mixed effect modeling in analgesia trials. Anesth Analg. 2008;107:9-10,19 and 
Joint hypothesis testing and gatekeeping procedures for studies with multiple 
endpoints. Anesth Analg 2012;114:1304-1720 
Includes a statistical power analysis but does not provide a 1 or 2 sentence 
summary of previous studies showing what is the minimum clinically important 
difference 
Beyond effect size: consideration of the minimum effect size of interest in 
anesthesia trials. Anesth Analg 2012;114:471-521 
Assesses concordance (agreement) in trends of hemodynamic variables 
A critical review of the ability of continuous cardiac output monitors to measure 
trends in cardiac output. Anesth Analg 2010;111:1180- 9222 
Includes a composite endpoint 
Design and analysis of studies with binary-event composite endpoints: 
Guidelines for anesthesia research. Anesth Analg 2011;112:1461-7123 
Reports multiple uncorrected P-values as “P < 0.05” 
Publication bias, retrospective bias, and reproducibility of significant results in 
observational studies. Anesth Analg 2012;114:931-224 
Includes binary operating room management data such as cancellation rates 
Validation of statistical methods to compare cancellation rates on the day of 
surgery. Anesth Analg 2005;101: 465-7325, 26 
Includes continuous operating room management data such as turnover times 
Numbers of simultaneous turnovers calculated from anesthesia or operating 
room information management system data. Anesth Analg 2009;109:900-527 
Includes prediction probabilities 
A program for computing the prediction probability and the related receiver 
operating characteristic graph. Anesth Analg 2010;111:1416-2128 
Includes a Bland-Altman plot 
Let’s think clinically instead of mathematically about device accuracy. Anesth 
Analg 2011;113:89-9129 
Includes logistic regression or propensity score analysis, and procedure or 
duration is used as an independent variable 
Statistical Grand Rounds: Importance of appropriately modeling procedure and 
duration in logistic regression studies of perioperative morbidity and mortality. 
Anesth Analg 2011;113:1197-20130 
25 
 If the guidance in Table 2 is not clear, please consult a statistician for 
assistance with the statistical analysis. 
 
Results 
 The results are the most important part of the manuscript. 
 The presentation must minimize the possibility of misinterpretation of the 
study 
findings.31 
 Present results in a logical sequence in the text, tables, and illustrations. To the 
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extent possible, the order of presentation in the Results should match the order 
of 
presentation of the Methods. 
 Account for all subjects, e.g., number enrolled but not randomized, number 
withdrawn and for what reasons, etc. 
 Do not repeat large amounts of material in the text that are also presented in 
the 
tables or figures. However, commenting on key data from tables or figures is 
necessary to highlight the main findings. 
 Focus on the important results. 
 In the text, tables, and illustrations, present P values as the actual value 
rounded to 
the nearest one-hundredth if greater than 0.01 (e.g., P = 0.04) rather than as an 
inequality (e.g., P < 0.05). Inequality may be used in footnotes describing 
symbols that designate statistical significance in tables and figures (e.g., *P < 
0.05) and when statistical software uses an inequality to report very small P 
values (e.g., P < 0.001). 
 Use consistent rules for presenting numerical results. For example, if a 
numeric result appears in the abstract, the results, and a table, it must be 
reported with the same precision in each instance. 
 In general, determining that the difference between two groups is greater than 
0 at P < 0.05 is not an interesting result. Even the most trivial difference might be 
statistically significant if enough subjects were studied. The important questions 
are: 1) what are the confidence bounds for the difference between groups; and 2) 
is the difference large enough to matter scientifically or clinically? 
Discussion 
 Discussions should be focused and succinct. 
 The Discussion is typically less than 1000 words. 
 The Discussion should not be a comprehensive review of the literature. 
 The Discussion need not cite every previous study in the field. 
 The Discussion should not contain product advertisements, e.g., “this new 
product 
is conveniently packaged and may transform anesthesia and perioperative 
medicine.” 
 Do not claim to be the first to report something. This claim only invites angry 
Letters to the Editor. Claims of being the first to publish a finding are best made 
in 
retrospect. 
 Where possible, structure your Discussion in the same order in which the 
results 
were presented in the Results section. 
 Emphasize new and important aspects of the study and the conclusions that 
follow. 
 Succinctly relate the observations to other relevant studies. 
 Do not repeat data presented in the Results section, except as required for 
clarity. 
 All claims must be fully supported by the data. 
 Avoid claims that could be misinterpreted when taken out of context.31 
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 State the limitations of the study including the limitations of the materials and 
methods. State how the limitations temper the conclusions. 
 In the last paragraph link the conclusions with the goals of the study. If the 
study 
tested a hypothesis, state whether the hypothesis was proven, disproven, or the 
study was inconclusive. 
 
Tables 
 Preferably, tables should be embedded in the Word document although they 
can also be uploaded separately. 
 Use a separate page for each table. 
 Double-space each table’s entries. 
 Do not submit tables as photographs or pasted images. 
 Number the tables consecutively, and cite them consecutively (on first 
instance) in 
the text. Each table should have a brief title. Each column in a table should have a 
brief name. 
 Use footnotes (not table titles or column headings) for explanatory matter and 
definitions of abbreviations. Abbreviations must be described with footnotes 
even if 
they are defined in the text or in other tables. 
 For footnotes, use lower-case italicized letters in alphabetical order. 
 If you include a block of data, a table, or a figure from another source, whether 
published or unpublished, acknowledge the original source. 
 
Figures and Illustrations 
 Figures are preferred over tables for presenting data. 
 Important research findings should be visually evident in the accompanying 
figures. 
 For useful information on preparing digital art, please review the detailed 
instructions at http://art.cadmus.com/da/index.jsp. 
 You are encouraged to read The Visual Display of Quantitative Information by 
Edward Tufte,32 a superb treatise on statistical graphics, charts, and tables. 
 Design figures and illustrations with their published size in mind, i.e., 1 or 2 
columns wide. Large figures will be reduced. 
 Anesthesia & Analgesia publishes in full color, and encourages authors to use 
color 
to increase the clarity of figures. Standard colors should be used (black, red, 
green, blue, cyan, magenta, orange, and gray). Avoid colors that are difficult to 
see on the printed page (e.g., yellow) or are visually distracting (e.g., pink). 
Figure backgrounds and plot areas should be white, not grey. Axis lines and ticks 
should be black and thick enough to clearly frame the image. Axis labels should 
be large enough to be easily readable and printed in black. 
 The default formatting provided with Microsoft Excel is not acceptable for 
scientific graphics. There are numerous programs for creating scientific graphics 
that are more suitable than Excel (e.g., R, Origin, Prism, SigmaPlot, StatGraphics, 
S+). If you decide to use Microsoft Excel to create figures, please use fonts that 
are clear and appropriately sized for all axis names and labels. In general sans 
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serif fonts (e.g., Arial or Helvetica) are better for figures than serif fonts (e.g., 
Times). 
 Number figures consecutively. Supply a brief title for each. Cite figures in the 
text in consecutive, numerical order on first instance. 
 If a figure has already been published, acknowledge the original source. You 
must obtain and submit written permission from the copyright holder to 
reproduce the material when you submit the manuscript for review. 
Unpublished figures require permission of the author. Permission is required to 
reproduce any previously published material except for documents or figures in 
the public domain. 
 Define all abbreviations used in each figure. Repeat definitions of any 
abbreviations used in subsequent legends. 
 
References 
 All references must be generally available to readers. Cite references to articles 
only if they are published in peer-reviewed journals included in the Index 
Medicus. Unacceptable references include abstracts appearing only in meeting 
programs or abstracts more than 3 years old. These should be listed as footnotes. 
Number references consecutively in the order in which they are first mentioned 
in the text. Double-space between all lines of each reference and between 
references. 
 Cite references in text, tables, and legends using superscripted numbers after 
the punctuation in the order in which the citations appear in the text, tables and 
figure legends (e.g., Wong et al.1 described . . .). 
 The titles of journals must be abbreviated according to the style used in Index 
Medicus. 
 Verify all references against the original documents or Medline. 
(http://www.pubmed.gov) 
 Upload copies of “in press” references to Editorial Manager when the 
manuscript is submitted. 
 Check the citation list for duplicate entries. 
 Use the formats of the example references shown in Table 1 above as guides 
for 
formatting references. 




Standard journal article (list all authors, do not use “et al”) 
Dalal PG, Murray D, Cox T, McAllister J, Snider R. Sedation and anesthesia 
protocols used for magnetic resonance imaging studies in infants: provider and 
pharmacologic considerations. Anesth Analg 2006;103:863–8 
Books/monographs 
Zar JH. Biostatistical Analysis. 3rd ed. Upper Saddle River, NJ: Prentice-Hall, 1996 
28 
Supplemental Digital Content 
Supplemental digital content provides additional material too detailed for 
inclusion in the manuscript, or only accessible electronically (e.g., video, 
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simulation software). Supplemental digital content may include audio and video 
files, spreadsheets, additional figures and tables, appendices, data files, and 
statistical analysis programming code, simulations, and apps. Remove all patient 
identifiers from the supplemental digital content prior to uploading. 
Supplemental digital content should be labeled as to whether the content is to be 
published in the print journal, as an online supplement, or not published and for 
reviewers only. Please cite the supplemental digital content in the text along with 
a very brief description, for example, “Supplemental Video 1, dilated right 
coronary artery...” 
Because supplemental digital content is part of the overall submitted 
manuscript, make every effort to have the supplement clearly formatted and 
organized. More detailed instructions can be found online at 
http://sites.google.com/site/lwwsdcauthorchecklist. 
Authors are urged to share raw data whenever possible. Raw data are invaluable 
to the community of investigators working to move a discipline forward. The 
submission of raw data as supplemental digital content also provides an external 
storage site for the authors’ data, helping to ensure that the original research 
data are preserved. Lastly, including raw data as a supplemental digital content 
enhances the transparency of the published research and the peer review 
process. 
Excel spreadsheets are commonly used to share raw data. ASCII “CSV” (comma 
separated values) files are also acceptable. All data shared as a web supplement 
should be appropriately de-identified to protect patient privacy. 
 
Book chapter 
Eger EI II. Uptake and distribution. In: Miller RD, ed. Miller’s Anesthesia. 6th ed. 
Philadelphia: Elsevier Churchill Livingstone, 2005:131–53 
Published proceedings 
DuPont B. Bone marrow transplantation in severe combined immunodeficiency 
with a paper unrelated MLC compatible donor. In: White HJ, Smith R, eds. 
Proceedings of the third annual meeting of the International Society for 
Experimental Hematology. Houston: International Society for Experimental 
Hematology, 1974:44-6 
Website 
Do not use as a reference. May be used as a footnote listing the URL and the date 
it was last accessed by the author, e.g., NIH Request for Applications. Available at: 
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-08-005.html. Accessed 
May 6, 2010. 
If authors are not comfortable sharing data online as supplemental digital 
content, they may indicate as a footnote on the title page which author (if any) 
can be contacted via e-mail for the raw data. 
 
Video 
Please follow the guidelines below for submitting supplemental video (including 
video for Echo Rounds and Echo Didactics) and audio files: 
 The preferred video file formats are MPEG-4 (MP4), QuickTime (MOV), and 
Windows Media Video (WMV). Please preview video clips on both Windows and 
Macintosh platforms to be certain they play correctly. The review process will be 
delayed if the Editorial Office cannot play the video clip. 
 88 
 Deliver still images from video clips in high-resolution JPEG or TIFF formats. 
 Individual video clips should not exceed 15 MB. 
 Use video-compression software to reduce video size if necessary. Optimal 
video 
frame dimensions are 480 360 pixels and 640 480 pixels. Videos of 320 240 
pixels have inadequate resolution for teaching purposes. Video clips are typically 
15–25 seconds. 
 Combinations of clips: If several video clips are combined, for example, several 
transesophageal echocardiographic loops, please provide adequate time for each 
segment and leave a suitable gap between the videos. Use appropriate labeling to 
ensure that the viewer can understand the timing of the pathology and events. 
Labeling can be added with video editing programs, such as Adobe Premiere or 
iMovie. 
 Patient identifiers: All patient identifiers must be removed from video clips 
and still images, including the date of the study. 
 For echocardiographic video, please consult Rokey and Vick. Masking Personal 
Health Information on Real-time Echocardiographic Images.33 
Audio 
 Submit audio files in WAV or MP3 formats. 
Units of Measurement 
Anesthesia & Analgesia serves an international audience. For this reason, 
Système International (SI) units are preferred. 
We recognize that authors and readers unfamiliar with SI units have difficulty 
interpreting them. Authors unfamiliar with SI units may make undetected errors 
if they convert their measurements to SI units. To minimize the chance of 
conversion errors, authors should submit manuscripts using the units of 
measurement used in the study, or the units that are used clinically at the 
author’s institution. These are the units that will appear in the published 
manuscript. 
30 
Updated October 2015 
Readers may readily convert published units to units of their choice using 
commonly available conversion tables. Anesthesia & Analgesia provides a 
spreadsheet for unit conversion available at http://www.aaeditor.org/units.xls. 
A more complete conversion table can be found in the American Medical 
Association Manual of Style, A Guide for Authors and Editors, Chapter 15: Units 
of Measure, Table 4: Conversions from Conventional Units to Système 
International (SI) Units, pp 486–503.34 
Abbreviations 
AAWP: Avoid Abbreviations Whenever Possible. Idiosyncratic abbreviations 
make text difficult to read. Abbreviations widely used within a narrow discipline 
can make a manuscript uninterpretable to the interested reader from outside 
that discipline. 
Do not create new or unusual abbreviations. For example, if the paper refers to 
the paw pressure test, just call it the paw pressure test throughout the paper, not 
the PPT. The added length of spelling out words is more than compensated for 
by the increased readability of your manuscript when words are spelled out. 
When it is necessary to use an abbreviation, at the first mention of an 
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abbreviated term in the abstract, text, each figure legend, and each table, write 
the unabbreviated term first, immediately followed by the abbreviation (within 
parentheses). For subsequent uses of the term in the same section use the 
abbreviation without parentheses. 
Please do not use abbreviations to decrease the word count of a manuscript. 
Clarity is more important than brevity. If a term is used fewer than 3 times, an 
abbreviation is unnecessary. 
Write as you speak. An electrocardiogram might be called an ECG, or EKG, so it is 
acceptable to abbreviate it as ECG (after it is spelled out on first use). However, 
spell out words if there is any possible ambiguity. This will help clarify the 
manuscript on morphine sulfate kinetics in multiple sclerosis patients with severe 
mitral stenosis undergoing maxillary sinus surgery and analyzed with Microsoft 
Excel. 
Consult the following sources for abbreviations: 





 American Medical Association. Manual of Style. 10th ed.9 
Updated October 2015 
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SUBMITTING YOUR MANUSCRIPT 
1. Go to Editorial Manager at http://aa.edmgr.com, or access the same site from 
either www.iars.org where the link can be found under “Journal  Submit an 
Article” or www.anesthesia-analgesia.org where the link can be found under “For 
Authors.” 
2. If you have not previously submitted a manuscript to Anesthesia & Analgesia or 
reviewed for the Journal, then you must click “Register” to create a username 
and password and create a new account. We recommend that your username be 
your e- mail address, but this is not required. 
What Happens After Submission? 
Manuscripts are reviewed by the Editorial Office to make certain that the 
submission contains all required elements and is properly formatted. The 
Editorial Office will not forward manuscripts to the Editor-in-Chief if the 
manuscript is not complete. An e-mail will be sent to the author describing any 
changes necessary to conform to our submission guidelines. 
Manuscripts are then forwarded to the Editor-in-Chief, who makes an initial 
assessment of the manuscript. This assessment includes screening for 
plagiarism, verifying compliance with the guidelines for ethical conduct of 
research described on page 5, and assessing scientific merit. If the manuscript 
does not appear meritorious or is not appropriate for Anesthesia & Analgesia the 
manuscript will be rejected with an explanation that it has not been forwarded 
for external peer review. 
If the manuscript appears meritorious and appropriate for the Journal, the 
Editor-in-Chief assigns the manuscript to the appropriate Section Editor or 
serves as the handling editor if the manuscript falls within the “General” section 
of the Journal. Authors are encouraged to suggest the section of the Journal they 
believe is best suited for their manuscript. The Editor-in-Chief considers authors’ 
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suggestions when assigning a manuscript to a section within Anesthesia & 
Analgesia. 
Upon receiving the manuscript from the Editor-in-Chief, the Section Editor 
makes an initial assessment of the manuscript. The Section Editor determines 
whether the manuscript is meritorious and verifies that the assignment of the 
manuscript to his or her section is appropriate. If the manuscript meets these 
criteria it is sent for peer review. 
Authors are encouraged to recommend specific reviewers with the necessary 
expertise to assess their paper. These recommendations are helpful to handling 
editors. Authors may also request that their work not be assessed by specific 
reviewers. Author recommendations regarding specific reviewers are always 
considered when assigning reviewers, but the handling editor may choose to not 
follow these suggestions. 
Acceptance of manuscripts is based on importance, originality, scientific rigor, 
and clinical relevance. Reviewers submit their critiques of the manuscript to the 
Section Editor using Editorial Manager. The Section Editor drafts an initial 
decision letter weighing the assessments of the reviewers and his or her own 
evaluation of the manuscript. This decision letter is forwarded to the Editor-in-
Chief, who reviews and may modify the decision. The decision letter is then 
forwarded by the Editor-in-Chief to the Editorial Office, where it undergoes final 
editing. The Editorial Office sends the final decision letter to the author by e-mail. 
Anesthesia & Analgesia currently publishes less than one-quarter of the 
manuscripts submitted, making it among the most selective journals in the 
specialty. If a manuscript is rejected and the author believes that the reviewers’ 
critiques can be addressed, the author may appeal the rejection by sending a 
letter to the Editor-in-Chief at editor@anesthesia- analgesia.org. Appeals are 
generally granted, provided the author makes a convincing argument that the 
issues can be addressed in the revision, and the dialog is respectful. Rejected 
manuscripts resubmitted without permission from the Editor-in-Chief will be 
rejected without further review. 
Sometimes we recommend that a rejected manuscript be resubmitted to 
Anesthesia & Analgesia as a Letter to the Editor. This occurs when a rejected 
manuscript contains an interesting observation that our readers would value. If 
the manuscript is rejected with a recommendation to resubmit as a Letter to the 
Editor, the manuscript must be revised to meet the guidelines for Letters to the 
Editor described on page 14. The letter will be handled by the Correspondence 
Editor, and evaluated on its own merits. The Correspondence Editor is under no 
obligation to accept a Letter to the Editor submitted at the suggestion of a 
Section Editor. 
Authors can expect an initial decision on submitted manuscripts or letters within 
6 weeks. Nearly all accepted manuscripts undergo several rounds of revision and 
copyediting to produce the best possible published paper. 
Once the Section Editor decides that a manuscript is ready for publication, a 
provisional acceptance letter is forwarded to the Editor-in-Chief. If the Editor-in-
Chief accepts the recommendation, the manuscript is accepted. The 
corresponding author is notified by e- mail. Following acceptance the manuscript 
is reviewed by the Editorial Office for scientific English, clear writing, and 
conformance with Journal style. The Editorial Office may return the manuscript 
to the Section Editor or Editor-in-Chief if portions are incomprehensible. The 
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Editorial office frequently contacts authors for clarifications about specific text 
or references. Once the Editorial Office has completed its copyediting the 
manuscript is forwarded to the publisher. 
The publisher further edits the manuscript and prepares a “galley proof” of the 
typeset manuscript. The author will receive galleys from the publisher via an e-
mail link. It is essential that authors carefully review the galley proof. 
Manuscripts are in the publication queue when the galley proof is created, so any 
delay in reviewing the galley proof may delay publication of the manuscript. 
Authors are strongly encouraged to return the corrected galley proof within two 
working days to ensure that any corrections are detected before the Journal is 
printed. Errors in printed manuscripts are almost always present in the galley 
proof and would have been detected before publication had the author carefully 
reviewed the galley proof. For example, authors occasionally notify the Journal 
that an author’s name has been misspelled. This is always a result of an author 
failing to carefully read the names of the authors in the galley proof. 
The galley proof will include “author queries” which must be answered. These 
appear in the margin of the proof, and are summarized at the end of the galley 
proof. 
Galley proofs are only for vetting the text, layout, and typesetting of the 
manuscript prior to publication. They should not be posted in a public forum, 
and distribution should be limited to coauthors. 
The average time from acceptance to printed publication is 4–6 months, 
although this can be as short as 3 months for very brief communications to as 
long as 1 year for manuscripts included in a collection of related papers. Most 
research reports appear online approximately 12 weeks after acceptance. 
The article is considered published when it appears online. 
Authors are encouraged to contact the Editorial Office at editor@anesthesia-
analgesia.org with any questions or concerns about the status of their 
manuscript throughout the submission, review, editing, and publication process. 
All communications must be civil, respectful, and collaborative. The Journal 
holds itself to this same standard in its dialog with authors. 
 
OPEN ACCESS 
LWW’s hybrid open access option is offered to authors whose articles have been 
accepted for publication. With this choice, articles are made freely available 
online immediately upon publication. Authors may take advantage of the open 
access option at the point of acceptance to ensure that this choice has no 
influence on the peer review and acceptance process. These articles are subject 
to the journal’s standard peer-review process and will be accepted or rejected 
based on their own merit. 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow 
perpetual unrestricted online access to their published article to readers 
globally, immediately upon publication. The article processing charge for 
Anesthesia & Analgesia is $3,000 A&A Case Reports is $500. The article 
processing charge for authors funded by the Research Councils UK (RCUK) is 
$3,800. The publication fee is charged on acceptance of the article and should be 
paid within 30 days by credit card by the author, funding agency or institution. 
Payment must be received in full for the article to be published open access. 
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Authors retain copyright 
Authors retain their copyright for all articles they opt to publish open access. 
Authors grant LWW a license to publish the article and identify itself as the 
original publisher. 
 
Creative Commons license 
Articles opting for open access will be freely available to read, download and 
share from the time of publication. Articles are published under the terms of the 
Creative Commons License Attribution-NonCommerical No Derivative 3.0 which 
allows readers to disseminate and reuse the article, as well as share and reuse of 
the scientific material. It does not permit commercial exploitation or the creation 
of derivative works without specific permission. To view a copy of this license 
visit: http://creativecommons.org/licenses/by-nc-nd/3.0. 
Compliance with NIH, RCUK and other research funding agency 
accessibility requirements 
A number of research funding agencies now require or request authors to submit 
the post- print (the article after peer review and acceptance but not the final 
published article) to a repository that is accessible online by all without charge. 
As a service to our authors, LWW identifies to the National Library of Medicine 
(NLM) articles that require deposit and transmits the post-print of an article 
based on research funded in whole or in part by the National Institutes of Health, 
Howard Hughes Medical Institute, or other funding agencies to PubMed Central. 
The revised Copyright Transfer Agreement provides the mechanism. LWW 
ensures that authors can fully comply with the public access requirements of 
major funding bodies worldwide. Additionally, all authors who choose the open 
access option will have their final published article deposited into PubMed 
Central. 
RCUK funded authors can choose to publish their paper as open access with the 
payment of an article process charge, or opt for their accepted manuscript to be 
deposited (green route) into PMC with an embargo. 
With both the gold and green open access options, the author will continue to 
sign the Copyright Transfer Agreement (CTA) as it provides the mechanism for 
LWW to ensure that the author is fully compliant with the requirements. After 
signature of the CTA, the author will then sign a License to Publish where they 
will then own the copyright. 
It is the responsibility of the author to inform the Editorial Office and/or LWW 
that they have RCUK funding. LWW will not be held responsible for retroactive 
deposits to PMC if the author has not completed the proper forms. 
FAQ for open access 
http://links.lww.com/LWW-ES/A48 
COPYRIGHT AND RETAINED RIGHTS 
Copyright Assignment Agreement 
Upon submission for all new submissions, we require each author to complete 
and sign a digital copyright assignment agreement which is then uploaded into 
Editorial Manager (under “Attach Files”) by the corresponding author. Please 
note that we no longer accept forms by fax or email. For more information visit: 
http://edmgr.ovid.com/aa/accounts/ifauth.htm. 
The copyright assignment agreement covers all submitted written material and 
supplementary digital content and assigns the copyright to the International 
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Anesthesia Research Society, owner of Anesthesia & Analgesia. If excerpts from 
copyrighted works are included in the submitted material, authors must obtain a 
written release before submission and provide credit to the original publication. 
In the case of material written as part of the duties of an employee, an authorized 
representative of the employer must also sign. If the submitted material or a 
portion of it has been created in the course of any author’s employment by the 
United States Government, it is called a “work of the U.S. Government” and is not 
subject to copyright. 
Preprints 
Upon acceptance of the article for publication, each author must remove any 
prior versions of this work (normally a preprint) that may have been posted to 
an electronic server. 
Retained Rights, Institutional Postings 
Except for copyright, other proprietary rights related to the submitted material 
(such as patent or other rights to any process or procedure, or reuse of the 
material for the personal noncommercial benefit of the author) are retained by 
the authors. Anesthesia & Analgesia will permit the author to deposit for display a 
“post-print” (the final manuscript after peer- review and acceptance for 
publication but before the publisher’s copyediting, design, formatting, and other 
services) 12 months after publication of the final article on his/her personal 
website, university’s institutional repository, or employer’s intranet. 
Compliance with NIH and Other Research Funding Agency Accessibility 
Requirements: A number of research funding agencies now require or request 
authors to submit the post- print to a repository that is accessible online by all 
without charge. As a service to our authors, based on your indication of funding 
on the copyright assignment agreement, the Journal will identify articles that 
require deposit and transmit the post-print of the articles to NIH Manuscript 
Submission System (NIHMS). Upon NIHMS request to the author, it remains the 
legal responsibility of the author(s) to validate the submission with the 
repository. 
Fair Use 
Authors can republish portions of their accepted manuscript, for personal 
noncommercial purposes, at their discretion. When this occurs, we ask that the 
article be attributed as published in the Journal. If an author wishes to reproduce 
an article in its entirety, exactly as published in the Journal, permission should be 
obtained through the “Request Permissions” link to the article on the journal’s 
online website. 
 
EXPECTATIONS OF AUTHORS 
The Journal has an overriding interest in research integrity. To fulfill this 
obligation, all authors must fulfill the following expectations: 
1. All authors must attest to having reviewed and approved the final manuscript. 
2. For research reports, brief reports, and technical communications a single 
author 
must be designated as the archival author. The archival author is responsible for 
maintaining the study records. The archival author will be contacted should 
questions about the data arise following publication. 
3. For research reports, brief reports, and technical communications with more 
than one author, at least two authors must attest to: 
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a. Having seen the original study data. 
b. Having reviewed the data analysis. 
4. Authors are expected to participate in any external review assessing the 
integrity of 
their research. Failure to fully cooperate with any inquiry into the integrity of 
their research may result in retraction of papers related to the research by 
Anesthesia & Analgesia. 
5. Authors should be prepared to make the research protocol, original research 
records, informed consents, IRB approvals, spreadsheets, and analyses available 
for review by the Journal should questions arise during or after the peer review 
process about the integrity of the data or the ethical conduct of the research. 
Authors should redact protected healthcare information and proprietary 
business information from research records and protocols to protect patient and 
organizational confidentiality prior to making the records available. 
6. Anesthesia & Analgesia recognizes that authors may have legitimate reasons 
for not providing raw data to the Journal. If such data are not provided, the 
Journal may elect not to consider the manuscript. Following publication, the 
Journal encourages authors to make data freely available to other investigators. 
The Journal acknowledges that the decision to share data rests with the authors 
and that there are legitimate reasons for authors declining such requests. 
7. Senior authors must accept responsibility for misconduct by junior authors 
under their mentorship. 
8. Authors understand that the Journal may make available to an author’s 
institution any communications between the author and the Journal if requested 
to do so by a review panel investigating possible academic misconduct under the 
auspices of the institution. 
9. Authors understand that journal editors may share information about 
academic misconduct with the editors of other journals, as misconduct 
frequently involves more than a single journal. 
10. Academic misconduct discovered during peer review may be publicly 
disclosed if disclosure is required to insure the integrity of the scientific record. 
 
RED FLAGS 
Red flags are issues identified during peer review that raise suspicion of 
improper conduct. Most red flags are the result of simple misunderstandings. 
However, red flags typically require that the author explain an issue uncovered 
during peer review to the editor. Red flags delay manuscript review, and place 
authors in the uncomfortable position of defending the integrity of their 
submission. 
Red flags are similar to conflict of interest concerns: 
1. They arise because of something discovered during peer review, 
2. Most are completely innocent, and 
3. Can be prevented by careful attention to full disclosure at the time of 
submission. 
This section reviews several common red flags to help authors anticipate 
concerns that might arise during peer review. The intent is to alert authors to 
potential issues so that they can provide clear explanations in their manuscript 
and cover letter, and thus avoid raising red flags. 
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Multiple Publications Derived from a Single Study 
In the interest of minimizing risk to human and animal subjects, as well as 
promoting efficient use of scarce research funds, investigators may pose several 
questions and make multiple measurements in a single study with the intent of 
publishing multiple manuscripts. Large longitudinal multicenter outcome trials 
often generate dozens of high quality manuscripts. 
The screening that manuscripts undergo to detect plagiarism is exquisitely 
sensitive to multiple submissions from a single study. Identification of 
undisclosed previous papers from a single study is a red flag for inappropriate 
data slicing into “minimum publishable units,” or attempting to publish the same 
research multiple times. The lack of disclosure suggests an intent to conceal the 
previous publications. 
To prevent this red flag from arising during peer review, the Journal has 
adopted the following three requirements when multiple papers arise from a 
single research study: 
1. The cover letter for every paper derived from the study should explain the 
need for dividing the study into multiple manuscripts. This requirement applies 
even if only one of the submissions is to Anesthesia & Analgesia. The Journal will 
consider the appropriateness of the division as part of the review process. 
2. In all manuscripts after the first published manuscript the investigator must 
disclose in the Methods section any data previously reported with appropriate 
citations to the earlier manuscripts. This practice is essential for scientific 
continuity. This disclosure requirement does not apply to previously published 
abstracts. 
3. Measurements must not interfere with each other. Such interference may 
happen in ways not evident at the time of the study. For example, measurements 
of pain thresholds may make it impossible to measure sedative effects. The 
potential for interfering measurements may not be evident if the pain thresholds 
and sedation effects are reported in separate manuscripts that are not 
appropriately cross- referenced. If these requirements are met, then the 
submission is forwarded to peer review. However, if these requirements are not 
met, then authors are asked to explain the relationship of the new submission to 
their previous work prior to peer review. If the explanation is not satisfactory, 
then the matter may be referred to the author’s institution for further review. 
 
Multiple Publications Derived from a Single Database 
Many important outcomes are identified by querying large databases, such as 
those used for billing purposes, derived from medical records, or registries of 
patients and outcomes. These databases are often used by multiple investigators 
at multiple institutions. There may be no way for investigators to know what 
queries are being analyzed by other investigators. 
Investigators may pose a query to a database that is nearly identical to one 
previously posed to the same database. This raises a red flag, because of the 
very real possibility of duplicate publication. If an investigator is aware that a 
database has been used for similar queries, then the cover letter and manuscript 
should describe the similar queries made from the database and list the resulting 
manuscripts, regardless of whether they are published or merely under review. 
Extending a Study 
Occasionally authors will extend a previously published study by adding 
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additional subjects, groups, or years of follow-up assessment. This is typically 
entirely appropriate, provided it is fully explained in the study methodology. It is 
a red flag if it is discovered during peer review that the data in the manuscript 
represent new data added to previously published data. 
 
Failure to Self-Reference Recent Publications 
Authors typically reference their previous work when discussing new findings in 
an area of research. It is a red flag when authors fail to reference their own 
previous work, particularly if it is similar to the submitted manuscript. Failure to 
reference a recent paper suggests that the authors are attempting to hide it from 
peer reviewers. 
 
Failure to Advise the Editor and Reviewers of Concurrent Publications 
If the authors have submitted a similar manuscript to another journal for 
consideration, they should include it in the references as “submitted for 
publication.” If the manuscript has extensive overlap, then the manuscript itself 
should be included with the submission to permit the reviewers to assess 
overlap. Failure to report concurrent submission of a similar publication is a red 
flag, because it prevents the reviewers from assessing the novelty of the 
submission to Anesthesia & Analgesia. 
 
Changes in Research Methodology Identified During Peer Review 
In many areas of research only a handful of experts regularly review 
manuscripts. If a paper has been rejected by one journal, and submitted to 
another journal, there is a high probability that the same reviewer will assess 
both submissions. It is a red flag when reviewers identify inexplicable changes 
in the paper. Reviewers have identified the introduction of new groups into a 
“prospective randomized trial,” changes of inhaled anesthetics or intravenous 
drugs, changes in drug dose, and different outcomes for study groups in papers 
that they have previously reviewed for other journals. 
Authors submitting a previously rejected manuscript should anticipate that the 
same reviewers will see the submission. Any significant change in the 
methodology or results should be explained in the cover letter, so that a red flag 
is not triggered when the reviewer spots the difference. 
 
Request for Withdrawal 
It is unusual for authors to withdraw their manuscript during the peer review 
process. This is a red flag. If an author wishes to withdraw a manuscript while it 
is undergoing peer review, the author must submit the request in writing to the 
Editor-in-Chief at editor@anesthesia-analgesia.org. The letter must explain the 
request for withdrawal. Until the withdrawal is granted authors are expected to 
fully cooperate with the Journal in the peer review process. 
 
Misrepresentation 
Any misrepresentation in the peer review process raises a red flag, even if not 
directly related to the manuscript content. For example, misrepresentation of an 
author’s academic credentials, sources of funding, institutional affiliation, or 
registration of a clinical trial is not acceptable. 
Most misrepresentations are simple mistakes and readily corrected. However, to 
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avoid raising red flags, authors should advise the journal as soon as possible of 
any errors they have discovered in their representations. This will preclude 
discovery of the error during peer review, raising the specter of intentional 
deceit. Errors discovered after publication may result in publication of an 
Erratum for a simple oversight, or a Statement of Concern if the Editorial Board 
is concerned about intentional misrepresentation, or retraction. 
All communication between authors and the Journal must be honest. 
Occasionally the Journal discovers misrepresentations in authors’ responses to 
the questions posed during peer review, or in correspondence with the Editorial 
Board or the Editorial Office. This raises a red flag. Authors must vet the 
integrity of every statement to the Journal during the peer review process. 
 
Failure to Disclose Authors Affiliated with Industry 
As discussed on page 4, authors sometimes fail to list as authors individuals 
associated with industry who meet the stated requirements for authorship. 
Ghostwriting is an example of this, where the contribution of the author of the 
text is not acknowledged, sometimes in an effort to hide the contribution of the 
study sponsor. This is a red flag, because it denies reviewers, and readers, access 
to disclosure of conflicts of interest that may have biased the manuscript. 
Additionally, it denies scientists from industry recognition of their work. All 
individuals meeting the requirements of authorship must be listed as coauthors, 
or an explanation provided for why these individuals are not authors. 
 
ACADEMIC MISCONDUCT 
Anesthesia & Analgesia is a member of the Committee on Publications Ethics 
(COPE) Code of Conduct for Editors of Biomedical Journals, and adheres to 
COPE’s Good Publication Practice (see http://publicationethics.org). 
The US Public Health Service’s Office of Research Integrity has devoted a 
considerable amount of effort to help institutions and authors understand 
responsible conduct of research. We strongly recommend that authors utilize 
this excellent resource, available at http://ori.dhhs.gov. 
 
Plagiarism 
Plagiarism is the use of previously published material without attribution. 
Anesthesia & Analgesia’s policy on plagiarism is described in a 2011 editorial.35 
Prior to peer review all manuscripts are screened for plagiarisms by the Editor-
in-Chief using iThenticate. The screening process identifies passages of text that 
have been previously published. Text copied from previously published work is 
interpreted using the following taxonomy: 
 Intellectual theft is misrepresentation by an author that words and ideas 
previously published by another author represent the plagiarist’s own 
scholarship. It is the most serious form of plagiarism. Intellectual theft identified 
during screening results in immediate rejection of the manuscript and a request 
for an explanation from the author. 
 Intellectual sloth is the use of the words of another author to avoid the effort 
of writing new text. It commonly occurs when descriptions of research 
methodology are taken from prior publications. It is less serious than intellectual 
theft, because the text is generic and of no particular value. Submissions 
containing intellectual sloth are typically returned to the authors with a request 
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that the copied text either correctly cite the original author or be rewritten in the 
authors’ own words. 
 Plagiarism for scientific English occurs when authors uncomfortable using 
scientific English compose their manuscripts as a patchwork of previously 
published sentences and paragraphs. Papers constructed in such a manner are 
rejected outright, primarily because patchwork plagiarism suggests that the 
authors may not understand the text they have submitted for publication. 
 Technical plagiarism is the use of verbatim text not identified as verbatim, 
but referenced to the original source. The offense is a technical one, and authors 
are simply asked to correct it prior to peer review. 
 Self-“plagiarism” occurs when an author uses his or her verbatim words from 
a previous manuscript in a new submission. Provided the authors are not 
engaged in duplicate publication, the Journal does not view “self-plagiarism” as 
misconduct. Authors are permitted to reuse their own words, and are 




Duplicate publication is prior publication of a manuscript with considerable 
content overlap, particularly in the research results, by the same author or co-
authors. Prior 
publication may be in the same language or it may be a translation (usually from 
the author’s native language to English). If a manuscript has been published 
previously, the submission to Anesthesia & Analgesia will be rejected unless it 
has already been published in which case it will be retracted. 
We request that authors inform the Journal when results of a submitted 
manuscript have been previously published in any venue. Several websites 
aggregate posters from society meetings. If the online poster discloses all of the 
results in the submission, then the poster may be considered prior to 
publication. 
The following forms of prior publication of research results are not considered 
prior publication of a submission: 
1. Prior publication of an abstract at a scientific meeting. 
2. Prior publication of study results in product labeling (e.g., the FDA Package 
Insert). 
3. Prior publication of study results in a patent application. 
There is sometimes value in publishing in English an important manuscript 
previously published in another language. Anesthesia & Analgesia will consider 
such submissions, however, they must be accompanied by a letter from the 
copyright holder of the original publication granting Anesthesia & Analgesia 
permission to publish the work. 
There is sometimes value in publishing Editorials, Guidelines, or other articles in 
more than one journal. This is always planned in advance by the involved 
journals. One journal is designated the primary publication. In all other journals 
the paper is only published after receiving permission from the copyright holder, 
and the primary publication is explicitly acknowledged as the original 
publication. 
Duplicate submission is concurrent submission of a nearly identical manuscript 
to two journals. Duplicate submissions identified during peer review will be 
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immediately rejected. Duplicate submissions that are discovered after 
publication will be retracted. 
 
Data Falsification 
Data falsification is any manipulation of data that is not disclosed in the 
publication. This can include editing data (removing outliers, altering values), 
fabricating data, taking data from a previous publication, or misrepresenting the 
data analysis. Data falsification is fraud. 
Anesthesia & Analgesia has a zero tolerance policy on fraud.36,37,38 If fraud is 
discovered during peer review the manuscript will be rejected. If fraud is 









Journal Policy on Misconduct 
Anesthesia & Analgesia reviews all allegations of academic misconduct. The 
Journal follows the protocol recommended by the Committee on Publication 
Ethics.d When credible evidence of misconduct is brought to the Journal’s 
attention, the Journal will bring the concerns to the author. If the author fails to 
respond, or responds but does not adequately address the concerns, the Journal 
will take the concerns to the institution. If the institution is unwilling to 
investigate the concerns, then the Journal will take the concerns to the 
appropriate government agencies.38,39,40 
Anesthesia & Analgesia has a policy of full cooperation with any institutional 
inquiry into allegations of academic misconduct. The Journal will provide the 
institution with copies of all submissions and correspondence. In general 
Anesthesia & Analgesia will follow the recommendations of an institutional 
inquiry. However, the Journal is not bound by the finding of the inquiry, and may 
elect a different course of action if the objectivity of the inquiry is questioned.41 
Although peer review is considered confidential, Anesthesia & Analgesia 
recognizes a responsibility to notify research institutions, other journals, and 
occasionally our readership when significant misconduct is discovered during 
peer review.38 
When academic misconduct is identified the Journal may institute sanctions 
against an author, ranging from requesting a Letter to the Editor acknowledging 
the error and voluntarily retracting a manuscript, to a lifetime ban on publication 
in Anesthesia & Analgesia. 
Updated October 2015 







Anesthesia & Analgesia exists for the benefit of current and future patients under 
the care of health care professionals engaged in the disciplines broadly related to 
anesthesiology: perioperative medicine, critical care, and pain management. The 
Journal furthers the care of these patients by reporting the fundamental 
advances in the sciences of these clinical disciplines, and by documenting the 
clinical, basic science, administrative, and educational advances that guide 
therapy. The Journal seeks a balance between outstanding basic scientific 
reports and definitive clinical and management investigations. The Journal 
welcomes original manuscripts reflecting rigorous analysis, even if unusual in 
style and focus. 
Anesthesia & Analgesia accepts a limited number of the manuscripts submitted 
for publication. However, the Journal is genuinely honored by every submission. 
In exchange for authors following this Guide for Authors, the Journal promises to 
consider every manuscript thoughtfully. In addition, the Journal promises to 
treat all authors with the respect and dignity they have so thoroughly earned by 
their dedication to improving the health and well-being of patients. 
 
ADDENDUM 
Many members of the Editorial Board of Anesthesia & Analgesia serve on the 
editorial boards of other journals. Anesthesia & Analgesia acknowledges the 
contribution of these editorial boards to these guidelines through our 
overlapping editors. Neither Anesthesia & Analgesia nor the International 
Anesthesia Research Society (IARS) wishes to claim ownership of the principles 
or text in these guidelines. The IARS hereby grants societies, journals, and 
individuals the right to paraphrase or quote verbatim sections of any length from 
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